# Medical Question & Answer

**Sample ID**: cd721b16-8421-4b72-bd20-fa925861ecb6
**Dataset Index**: 4424

---

## Question

is TIBC low in chronic kidney disease?

---

## Answer

> Let's see… What do we have here? The user is asking whether total iron-binding capacity (TIBC) is low in chronic kidney disease (CKD). Let's break this down step-by-step. First, I need to think about what TIBC represents physiologically and how inflammation affects it. Then, I should verify direct clinical evidence of baseline TIBC values in CKD cohorts. Next, I will examine how therapies that modulate iron handling (SGLT2 inhibitors, HIF-PH inhibitors) change TIBC in CKD. After that, I need to reconcile any conflicting data and consider modifiers like malnutrition and acute-phase effects. Finally, I will synthesize a clear conclusion and note practical implications for iron assessment in CKD.

> Let me first confirm the physiology and the inflammatory context. TIBC is a surrogate for serum transferrin, which is synthesized by the liver and falls during inflammation because transferrin is a negative acute-phase reactant; CKD is a pro-inflammatory state with elevated hepcidin that restricts iron availability, so I initially thought TIBC would be suppressed in CKD, which would make TIBC appear "low" on labs [^114JLXDd] [^112Vtput] [^1111Eyrw].

> Wait, let me verify this assumption against direct clinical data before concluding. In phase 3 trials of vadadustat for CKD anemia, mean baseline TIBC in all groups was below the lower limit of the population reference range (250–425 μg/dL), indicating that untreated CKD is indeed associated with low TIBC relative to population norms, which supports the idea that baseline TIBC is low in CKD [^117RBFbG]. I should also double-check observational data: a cross-sectional CKD cohort showed TIBC declined with advancing CKD stage, again consistent with lower TIBC as kidney function worsens [^112knGx7].

> Hold on, let's not jump to conclusions — what happens when we stimulate erythropoiesis or alter iron handling in CKD? I need to check whether TIBC rises under such conditions. In CREDENCE, canagliflozin increased TIBC by about 2.1% over 12 months versus placebo, suggesting improved iron utilization and a compensatory rise in transferrin/TIBC during enhanced erythropoiesis in CKD [^111iyJxW] [^112yzrqP]. Similarly, HIF-PH inhibitors (vadadustat, roxadustat, daprodustat) consistently increase TIBC and transferrin while decreasing ferritin and hepcidin, reflecting increased iron demand and mobilization during stimulated erythropoiesis in CKD [^117RBFbG] [^117EbSbL] [^115LMGR6]. Even IL-6 blockade with ziltivekimab increased TIBC in CKD, reinforcing that reducing inflammation can modulate iron indices, including TIBC, in this population [^114A2x8B].

> Hmm, wait a minute — this creates a paradox I should reconcile. Transferrin is a negative acute-phase reactant, so inflammation should suppress TIBC; yet in CKD cohorts, baseline TIBC is often low, and when erythropoiesis is stimulated (SGLT2 inhibition, HIF-PH inhibition, IL-6 blockade), TIBC rises. Let me think about this carefully: chronic inflammation in CKD tends to keep TIBC toward the low end of normal or below normal, but a sufficiently strong erythropoietic drive can overcome that acute-phase suppression and increase transferrin synthesis, thereby raising TIBC, which explains why interventional studies show TIBC increases despite ongoing CKD inflammation [^117RBFbG] [^111iyJxW] [^114A2x8B]. I should also note that mechanistic and translational data show that CKD-associated inflammation can produce hypoferremia with elevated ferritin and hepcidin, while still permitting TIBC to increase when erythropoiesis is stimulated, aligning with the clinical observations [^1111Eyrw].

> But wait, what if malnutrition is present — could that confound this picture? I need to ensure I account for nutritional status. In chronic inflammatory conditions, including CKD, malnutrition can suppress hepatic protein synthesis, potentially lowering transferrin and TIBC independently of erythropoietic demand; this effect can exaggerate low TIBC beyond inflammation alone, complicating interpretation and sometimes blunting the TIBC response to therapy [^114JLXDd]. Therefore, low TIBC in CKD reflects both the negative acute-phase effects of inflammation and, in some patients, nutritional constraints, with the direction of change also modulated by the strength of erythropoietic drive [^114JLXDd].

> Let me synthesize and make sure I'm precise. Baseline TIBC in untreated CKD is commonly low or at the low end of normal due to inflammation-driven suppression of transferrin, and TIBC tends to decline as CKD progresses; however, interventions that increase erythropoiesis (SGLT2 inhibitors, HIF-PH inhibitors, IL-6 blockade) raise TIBC, indicating that the erythropoietic signal can override inflammatory suppression in many patients [^117RBFbG] [^112knGx7] [^111iyJxW] [^117EbSbL] [^114A2x8B]. So, the answer is nuanced: yes, TIBC is generally low in CKD at baseline, but it is dynamic and can increase meaningfully when iron demand rises or inflammation is targeted, which is clinically relevant for iron assessment and treatment planning [^117RBFbG] [^111iyJxW].

> I should confirm the practical implications. Low TIBC in CKD complicates iron-status interpretation, especially when used to calculate transferrin saturation (TSAT), because a low denominator can artifactually raise TSAT despite true iron restriction; guidelines emphasize not relying on TSAT or ferritin in isolation and instead integrating TSAT with ferritin, reticulocyte hemoglobin content, or percent hypochromic red cells, and reassessing iron status serially during ESA or iron therapy [^114JLXDd] [^112KFCtq] [^1124wFVr] [^111vEPEQ]. I need to ensure I state that clearly: in CKD, low TIBC does not exclude iron deficiency; rather, it signals the need to interpret TSAT cautiously and to consider functional iron deficiency even when ferritin is normal or high [^116RmEyQ] [^114JLXDd].

> Final take: I should double-check that my conclusion aligns with both the baseline data and interventional signals. Yes — TIBC is typically low in untreated CKD because inflammation suppresses transferrin, but it can rise when erythropoiesis is stimulated or inflammation is reduced; therefore, "low" is the correct baseline characterization, with the caveat that TIBC is labile and responsive to therapy in CKD [^117RBFbG] [^112knGx7] [^111iyJxW] [^117EbSbL] [^114A2x8B].

---

In CKD, **TIBC is typically low or normal-low** because transferrin synthesis is suppressed by chronic inflammation and low nutritional status [^112knGx7] [^114JLXDd]. This pattern reflects functional iron deficiency — normal or high ferritin with low TSAT — and is common in CKD. TIBC may rise with IV iron or ESAs as iron availability improves, but it remains a less reliable marker in CKD; clinicians should interpret TIBC alongside ferritin and TSAT to guide therapy [^113QydfX] [^111vEPEQ].

---

## Pathophysiology of iron metabolism in CKD

CKD alters iron metabolism through **inflammation-driven hepcidin excess**, which reduces iron absorption and release from stores, causing functional iron deficiency even when ferritin is normal or high [^116f45jt] [^116DvtSE]. Transferrin synthesis falls in inflammation and malnutrition, so TIBC tends to be low or normal-low in CKD [^112knGx7] [^114JLXDd].

---

## TIBC levels in CKD patients

TIBC is generally **low or normal-low in CKD**, reflecting reduced transferrin from inflammation and malnutrition [^112knGx7] [^114JLXDd]. Clinical data show baseline TIBC below the normal range (250–425 μg/dL) in CKD, rising modestly with therapies that improve iron utilization [^117RBFbG] [^111iyJxW].

---

## Factors influencing TIBC levels in CKD

Several factors modulate TIBC in CKD:

- **Inflammation**: Elevated hepcidin suppresses transferrin synthesis, lowering TIBC [^notfound].
- **Nutritional status**: Protein-energy wasting reduces transferrin synthesis, lowering TIBC [^114JLXDd].
- **Iron supplementation**: IV iron or ESAs can increase TIBC as iron availability and erythropoiesis rise [^notfound].

---

## Clinical implications of low TIBC in CKD

Low TIBC in CKD signals **functional iron deficiency** and guides therapy:

- **Functional iron deficiency**: Low TIBC with normal/high ferritin and low TSAT indicates iron-restricted erythropoiesis common in CKD [^111CX2fR] [^112knGx7].
- **Therapeutic guidance**: Low TIBC with low TSAT supports IV iron or ESAs to improve anemia and reduce transfusion needs [^114goA2f] [^115oKPk3].
- **Monitoring**: TIBC helps track response to iron/ESA therapy and detect iron overload [^115LMGR6] [^113M5a7A].

---

## Clinical guidelines and recommendations

Guidelines emphasize **integrated iron assessment** in CKD:

- **Iron status assessment**: Use ferritin and TSAT to diagnose and monitor iron deficiency; TIBC supports interpretation but is less reliable alone [^116oqmLu] [^1124wFVr].
- **Iron supplementation**: IV iron is recommended when TSAT < 20% and ferritin < 100 ng/mL in non-dialysis CKD, with TIBC considered in context [^notfound].
- **Monitoring**: Reassess iron status every 1–3 months during therapy to optimize anemia management and avoid overload [^111vEPEQ] [^116V9Nh1].

---

## Summary of key findings

| **Parameter** | **Typical findings in ckd** |
|-|-|
| TIBC | Low or normal-low due to inflammation and malnutrition |
| Ferritin | Normal or high due to inflammation |
| TSAT | Low due to functional iron deficiency |
| Clinical implication | Functional iron deficiency common in CKD |

---

TIBC is **typically low or normal-low in CKD** because inflammation suppresses transferrin; interpret TIBC alongside ferritin and TSAT to identify functional iron deficiency and guide therapy [^112knGx7] [^1111Eyrw] [^112KFCtq] [^116ANoLV] [^113QydfX].

---

## References

### Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients [^1164jzew]. Nephrology, Dialysis, Transplantation (2015). Low credibility.

Fewer observations (n = 1−3) were available for the other dose regimens. Peak eEPO increased with dose but not frequency. At 2 mg/kg dose, the median peak level was 397 IU/L with a maximal observed value of 705 IU/L. Levels invariably returned to BL within 48 h.

Iron indices were evaluated in the EE subjects, most of whom were iron-replete at BL. Of the 116 subjects, 45% were already on oral iron prior to study (10–626 days), which was then continued. For the EE population, there was no significant difference in the fraction receiving oral iron between placebo (39%) and roxadustat (47%) groups. Daily iron dose pre- and poststudy ranged from 39 to 300 mg/day with a median of 130 mg/day without a difference between placebo and pooled roxadustat-treated groups. During the active study period, oral iron was begun in two roxadustat subjects only. No IV iron was permitted on study.

During 6 weeks of roxadustat-induced erythropoiesis, TSAT fell while total iron-binding capacity (TIBC) rose significantly, consistent with increased iron utilization. No significant changes occurred in the placebo group (Table 2).

Table 2.
Change from BL in mean serum iron, TIBC, ferritin and TSAT levels

Serum hepcidin levels decreased significantly during treatment with roxadustat (Figure 5). By 4 weeks, mean (± SD) hepcidin levels in the 1.5 and 2.0 mg/kg dose groups were both significantly decreased from BL (−150 ± 89.5, P = 0.048, and −225 ± 192 ng/mL, P = 0.0013, respectively) compared with the placebo group (−17.8 ± 114 ng/mL).

FIGURE 5:
Mean change from BL in serum hepcidin (EE population). Data from BIW and TIW groups were pooled for each dose level. Serum hepcidin was not measured in the roxadustat 1.0 mg/kg dose group. LOCF method was used to impute missing data. ✱ p = 0.048, ✱✱ p = 0.0013, intergroup two-sample t -tests comparing roxadustat change from BL with placebo change from BL. EOT was Day 29 (BIW) or Day 26 (TIW).

---

### AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia [^116NsNUx]. Gastroenterology (2020). High credibility.

AGA iron deficiency anemia diagnosis — In patients with anemia, the AGA recommends using a cutoff of 45 ng/mL over 15 ng/mL when using ferritin to diagnose iron deficiency, and in patients with inflammatory conditions or chronic kidney disease, other laboratory tests such as C-reactive protein, transferrin saturation, or soluble transferrin saturation, may be needed in conjunction with ferritin to diagnose iron deficiency anemia.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^115Hgx9N]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to insufficient evidence regarding the role of hepcidin measurement for the diagnosis of functional iron deficiency.

---

### Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China [^117EbSbL]. Nephrology, Dialysis, Transplantation (2017). Low credibility.

Background

FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadustat, CDAN name:), a HIF-PHI, in patients with anemia of chronic kidney disease (CKD), both patients who were dialysis-dependent (DD) and patients who were not dialysis-dependent (NDD).

Methods

In the NDD study, 91 participants were randomized to low (1.1–1.75mg/kg) or high (1.50–2.25mg/kg) FG-4592 starting doses or to placebo. In the DD study, 87 were enrolled to low (1.1–1.8mg/kg), medium (1.5–2.3mg/kg) and high (1.7–2.3mg/kg) starting FG-4592 doses or to continuation of epoetin alfa. In both studies, only oral iron supplementation was allowed.

Results

In the NDD study, hemoglobin (Hb) increase ≥ 1g/dL from baseline was achieved in 80.0% of subjects in the low-dose cohort and 87.1% in the high-dose cohort, versus 23.3% in the placebo arm (P < 0.0001, both). In the DD study, 59.1%, 88.9% (P = 0.008) and 100% (P = 0.0003) of the low-, medium- and high-dose subjects maintained their Hb levels after 5- and 6-weeks versus 50% of the epoetin alfa-treated subjects. In both studies, significant reductions in cholesterol were noted in FG-4592-treated subjects, with stability or increases in serum iron, total iron-binding capacity (TIBC) and transferrin (without intravenous iron administration). In the NDD study, hepcidin levels were significantly reduced across all FG-4592-treated arms as compared with no change in the placebo arm. In the DD study, hepcidin levels were also reduced in a statistically significant dose-dependent manner in the highest dose group as compared with the epoetin alfa-treated group. Adverse events were similar for FG-4592-treated and control subjects.

Conclusions

FG-4592 may prove an effective alternative for managing anemia of CKD. It is currently being investigated in a pivotal global Phase 3 program.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^112VZk15]. KDIGO (2012). Medium credibility.

Regarding medical management for chronic kidney disease, more specifically with respect to management of anemia, iron therapy, KDIGO 2012 guidelines recommend to avoid administering IV iron in patients with active systemic infections.

---

### Optimal oral iron therapy for iron deficiency anemia among US veterans [^112We6uT]. JAMA Network Open (2024). High credibility.

Methods

This cohort study was approved by the institutional review board of the Central Virginia US Department of Veterans Affairs Healthcare system. A waiver of informed consent was granted because the study was a retrospective analysis. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline.

Data Collection

Using the Veterans Health Administration Corporate Data Warehouse, we identified patients with IDA who received their first outpatient oral iron prescription (324 mg or 325mg of ferrous sulfate, ferrous gluconate, or ferrous fumarate) for 90 days, with at least 1 refill within 120 days of the first index prescription date between 2009 and 2019. IDA was defined as hemoglobin less than 12 g/dL (to convert to grams per liter, multiply by 10) and either (1) iron saturation (ISAT) less than 20% or (2) ferritin less than 50 ng/mL (to convert to micrograms per liter, multiply by 1). There was no official clinical practice guideline by the Veterans Health Administration on management of IDA, and oral iron was prescribed as per treating physician clinical discretion. Patients were classified into 3 dose groups: daily (once a day), multiple doses per day (MDD; ≥ 2 times per day), and alternate day dose (ADD) based on their oral iron dosing schedule.

Baseline laboratory data consisted of data collected closest to the index prescription date, but not older than 180 days. Follow-up laboratory data were collected from 30 to 180 days following the first oral iron prescription date (index prescription date). We have only included patients who had at least 1 follow-up hemoglobin measurement during this time. Ferritin, total iron binding capacity (TIBC; calculated in micrograms per deciliter [to convert to micromoles per liter, multiply by 0.179]), and ISAT were collected in those who met the aforementioned inclusion criteria. Therefore, every patient in the final cohort had continuous hemoglobin data, and within these patients, a subset had follow-up data on the other 3 iron indices.

Baseline estimated glomerular filtration rates (eGFR)were collected. Patients with an eGFR less than 15 mL/min/1.73 m 2, patients receiving dialysis, and patients with kidney transplants were excluded. Patients were further classified based on baseline eGFR into the cohort with NKF (eGFR ≥ 60 mL/min/1.73 m 2) and the cohort with CKD (eGFR ≥ 15 and < 60 mL/min/1.73 m 2).

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^116QRdA2]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy, iron deficiency with anemia, KDIGO 2012 guidelines recommend to consider administering a trial of IV iron (or alternatively a 1–3 month trial of oral iron therapy in patients with non-dialysis CKD) in adult patients with CKD and anemia not on iron or ESA therapy if an increase in hemoglobin concentration without starting ESA treatment is desired, transferrin saturation is < 30%, and ferritin is < 500 ng/mL.

---

### The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? [^112Yq2rp]. Clinical Journal of the American Society of Nephrology (2006). Low credibility.

Although the emergence of erythropoiesis-stimulating agents has revolutionized the anemia management of chronic kidney disease (CKD) in the past two decades, strategies to assess iron (Fe) status and to provide Fe supplementation have remained indistinct. The reported cases of hemochromatosis in dialysis patients from the pre-erythropoiesis-stimulating agent era along with the possible associations of Fe with infection and oxidative stress have fueled the "iron apprehension". To date, no reliable marker of Fe stores in CKD has been agreed on. Serum ferritin continues to be the focus of attention. Almost half of all maintenance hemodialysis patients have a serum ferritin > 500 ng/ml. In this ferritin range, Fe supplementation currently is not encouraged, although most reported hemochromatosis cases had a serum ferritin > 2000 ng/ml. The moderate-range hyperferritinemia (500 to 2000 ng/ml) seems to be due mostly to non-Fe-related conditions, including inflammation, malnutrition, liver disease, infection, and malignancy. Recent epidemiologic studies have shown that a low, rather than a high, serum Fe is associated with a poor survival in maintenance hemodialysis patients. In multivariate adjusted models that mitigate the confounding effect of malnutrition-inflammation, serum ferritin < 1200 ng/ml and Fe saturation ratio in 30 to 50% range are associated with the greatest survival in maintenance hemodialysis patients. Although ferritin is a fascinating molecule, moderate hyperferritinemia is a misleading marker of Fe stores in patients with CKD. It may be time to revisit the utility of serum ferritin in CKD and ask ourselves whether its measurement has helped us or has caused more confusion and controversy.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^113y5a6q]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy, safety, KDIGO 2012 guidelines recommend to guide subsequent iron administration in patients with CKD based on hemoglobin responses to recent iron therapy, as well as ongoing blood losses, iron status tests (transferrin saturation and ferritin), hemoglobin concentration, ESA responsiveness and ESA dose in ESA treated patients, trends in each parameter, and the patient's clinical status.

---

### Renal association clinical practice guideline on anaemia of chronic kidney disease [^113VCaPR]. BMC Nephrology (2017). Low credibility.

Summary of audit measures on anaemia of chronic kidney disease

Proportion of CKD patients with eGFR < 30 ml/min (using 4 variable MDRD or CKD-EPI) method with an annual Hb level.
Proportion of patients starting an ESA without prior measurement of %HRC or CHr (or serum ferritin and TSAT).
Proportion of patients on renal replacement therapy with Hb level < 100 g/L who are not prescribed an ESA
Each renal unit should audit the type, route and frequency of administration and weekly dose of ESA prescribed
The proportion of CKD Grade 4–5 patients with Hb 100–120 g/L
The proportion of patients treated with an ESA with Hb > 120 g/L
Mean (median) ESA dose in patients maintained on ESA therapy
Each renal unit should monitor ESA dose adjustments
Proportion of patients with serum ferritin levels < 100 microgram/L at start of treatment with ESA
Proportion of pre-dialysis and PD patients receiving iron therapy; type: oral vs. parenteral
Proportion of HD patients receiving IV iron
Prevalence of resistance to ESA among renal replacement therapy patients
Proportion of HD patients who received a blood transfusion within the past year

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^112ppsbt]. American Journal of Kidney Diseases (2007). Medium credibility.

Criteria for updating KDOQI anemia guidelines — triggers and surrogate endpoint considerations: An update is prompted when there is new evidence on important clinical outcomes, when evidence comes from studies adequately powered for the outcomes of interest, and when the new evidence would be likely to change the magnitude of the estimate of the effect or change the assessment of the balance of benefits and harms. Evidence from surrogate end point trials can prompt an update if criteria from the Users' Guide for a Surrogate End Point Trial are met, but the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study did not initiate an update because it examined a surrogate outcome (change in Hb) after short follow-up duration (6 weeks).

---

### Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease [^116f45jt]. BMC Nephrology (2018). Low credibility.

Background

Iron deficiency (ID) is the most common nutritional deficiency worldwide, affecting up to 25% of the population. A variety of causes are responsible for the depletion of iron stores, ranging from deficient dietary iron intake to increased blood loss (e.g. gastro-intestinal cancers, peptic ulcera). In addition, in chronic disease populations, due to the pro-inflammatory state that chronic diseases constitute, upregulation of serum hepcidin blocks iron absorption from the gut and iron release from the reticulo-endothelial system leading to reduced iron availability despite adequate stores. Indeed, in these populations, such as chronic heart failure (CHF) and chronic kidney disease (CKD), it has been shown that ID is highly prevalent and associated with an increased risk of morbidity and mortality, independent of potential confounders, including anemia.

The definition of ID is still a matter of debate. ID is generally divided into absolute ID (low iron stores) and functional ID (insufficient iron supply to the bone marrow despite sufficient iron stores). Due to the existence of both absolute ID and functional ID and the absence of an unequivocal gold standard, it remains challenging to correctly identify ID. Clinicians and epidemiologists alike predominantly rely on two frequently used markers, namely ferritin (for iron load) and transferrin saturation (TSAT, for iron transport availability). However, to date, no consensus has been reached which cutoffs of these parameters should be utilized to define absolute and functional ID per population. Except perhaps in the cardiology field where absolute ID is defined as a ferritin level < 100 μg/L, and functional ID as a TSAT < 20% accompanied by ferritin levels between 100 and 299 μg/L. Currently in nephrology, the Kidney Disease Improving Global Outcomes (KDIGO) committee recommends a trial of 1 to 3 months of oral iron therapy in non-dialysis CKD patients when TSAT levels are below 30% and ferritin below 500 μg/L. However, it is not known which cutoffs of ferritin and/or TSAT perform best with respect to predicting anemia, response to iron treatment or outcome.

Correctly defining which cutoffs of ferritin and TSAT associate with outcome would identify which patients are most at risk to develop these outcomes and thus in which patients correction of ID could potentially have the greatest benefit. Therefore, the present study was performed to define which cutoffs of serum ferritin and TSAT perform optimally for the risk of all-cause mortality, cardiovascular mortality, and risk of developing anemia in CKD patients.

---

### Should hemoglobin be normalized in patients with chronic kidney disease? [^116UZMd7]. Seminars in Dialysis (2002). Low credibility.

In the last decade the nephrology community has learned much about the impact of anemia on patients with kidney disease. Therapy of anemia can correct many of the symptoms which seriously compromise patient function. Despite the obvious benefits, controversy continues regarding the optimal target hemoglobin concentration both in patients prior to dialysis and in dialysis populations. In this editorial we review the clinical data that contribute to this controversy and the physiologic concepts underlying the treatment of anemia. Furthermore, we discuss the need to individualize hemoglobin targets for specific patient populations and the importance of early identification and treatment of anemia in patients with kidney disease. The economic impact of normalizing hemoglobin with the use of erythropoietin and intravenous or oral iron has affected clinical practice over the last decade. Current guidelines published by Kidney Disease Outcomes and Quality Initiative (KDOQI), the European Working Group on Anemia Management, and the Canadian Society of Nephrology all recommend target hemoglobin concentrations and thresholds for initiation of therapy and also suggest the need for reevaluation of current targets in light of new evidence. This editorial supports those guidelines and challenges the reader to critically evaluate current practice in the context of the accumulating data and the physiologic principles discussed herein. The therapy of anemia in patients with chronic kidney disease (CKD) is becoming increasingly sophisticated and is an essential component of care in patients with CKD. However, the effects of therapy will be most impressive when accompanied by the optimal care of all hemodynamic and metabolic abnormalities that are associated with CKD.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^116oqmLu]. KDIGO (2012). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to initial evaluation, KDIGO 2012 guidelines recommend to obtain the following tests as part of the initial evaluation of anemia in patients with CKD, regardless of age and CKD stage:

- CBC

- absolute reticulocyte count

- serum ferritin level

- serum transferrin saturation

- serum vitamin B12 and folate levels.

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^1122Cf7N]. American Journal of Kidney Diseases (2007). Medium credibility.

KDOQI anemia in chronic kidney disease — lack or loss of response advises to consider iron deficiency and 8 other categories of conditions, and provides specific information on evaluating and correcting persistent failure to reach or maintain intended Hb, defining hyporesponse features and listing associated disorders.

---

### Renal association clinical practice guideline on anaemia of chronic kidney disease [^114f7hTs]. BMC Nephrology (2017). Low credibility.

Rationale

A definition of adequate iron status is:
a serum ferritin
200–500 microgram/L in HD patients,
100–500 microgram/L in non-HD patients and
Either < 6% hypochromic red cells (HRC), or reticulocyte Hb content > 29 pg.
TSAT > 20%

The aim of iron treatment targets is to optimise anaemia therapy while minimising potential toxicity. Therapy targets aim at:
Minimising the ESA dose required to maintain target Hb levels in patients on ESA therapy and;
Maximising the Hb level and minimising the need to initiate ESA therapy to achieve target-range Hb levels in patients not on ESA therapy.

Increasing the Hb in anaemic patients places the greatest demand for iron in the erythropoietic tissues. During ESA induction therapy iron requirements will depend on the rate of erythropoiesis, the Hb deficit, and ongoing iron losses. Once the target Hb has been reached and Hb stabilised, the iron requirements will be dependent on ongoing iron losses.

---

### Hypoferremic response to chronic inflammation is controlled via the hemojuvelin / hepcidin / ferroportin axis and does not involve hepcidin-independent regulation of fpn mRNA [^1111Eyrw]. American Journal of Hematology (2025). Medium credibility.

3.2 Hjv Deficiency Is Protective Against‐Induced Hypoferremia and Anemia

As expected, wild type mice with CKD exhibited a significant (p < 0.001) ~40% drop in serum iron levels (Figure 2A) and transferrin saturation (Figure 2B), indicating a hypoferremic response to chronic inflammation. Along these lines, they presented with significantly elevated levels of serum ferritin (~65%, p = 0.0053; Figure 2D) and hepcidin (3.2‐fold, p < 0.0001; Figure 2E), in line with systemic inflammation. By contrast, serum iron and transferrin saturation, which are supraphysiological in Hjv −/− mice due to hemochromatosis, were not suppressed following intake of the adenine‐rich diet (Figure 2A, B). Under these conditions, serum ferritin was not further increased in Hjv −/− mice (Figure 2D), while serum hepcidin levels, which are suppressed due to Hjv deficiency, increased 2‐fold (p = 0.004, Student's t test) but remained subphysiological (Figure 2E). Notably, intake of the adenine‐rich diet boosted TIBC, reflecting serum transferrin levels, by ~30% (p < 0.0001) in both genotypes (Figure 2C). This is surprising because transferrin is a negative acute phase protein known to be suppressed under inflammation. Nonetheless, increased TIBC has previously been observed in mouse models of acute or chronic infection.

FIGURE 2
Hjv −/− mice are spared from CKD‐induced hypoferremia and anemia. Blood and serum from mice described in Figure 1 were used for hematological and biochemical analysis. (A) Serum iron; (B) Transferrin saturation; (C) Total iron binding capacity (TIBC); (D) Serum ferritin; (E) Serum hepcidin; (F) Hemoglobin; (G) Mean corpuscular volume (MCV); (H) Red cell distribution width (RDW); (I) Hematocrit. All data are presented as the mean ± SEM. Statistically significant differences are indicated in p values (ns: non‐significant). Analysis was performed with two‐way ANOVA and Tukey's multiple comparison test; differences in serum hepcidin between control and CKD Hjv −/− mice were also analyzed by the Student's t test.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^115JGYLR]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to measure mean cell volume and mean cell hemoglobin values at diagnosis of iron deficiency and for assessing trends over periods of weeks or months, but not for assessing acute changes in iron availability secondary to therapy with ESAs.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^112s7Cr6]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to view a reticulocyte hemoglobin content value < 29 pg as predictive of functional iron deficiency in patients receiving ESA therapy, and < 25 pg as suggestive of classical iron deficiency. View a reticulocyte hemoglobin equivalent value < 30.6 pg as predictive of the likelihood of response to IV iron therapy in patients with CKD on hemodialysis.

---

### Iron dextran [^113M5a7A]. FDA (2025). Medium credibility.

DOSAGE & ADMINISTRATION

Oral iron should be discontinued prior to administration of INFeD.

Dosage:

I. Iron Deficiency Anemia: Periodic hematologic determination (hemoglobin and hematocrit) is a simple and accurate technique for monitoring hematological response, and should be used as a guide in therapy. It should be recognized that iron storage may lag behind the appearance of normal blood morphology. Serum iron, total iron binding capacity (TIBC) and percent saturation of transferrin are other important tests for detecting and monitoring the iron deficient state.

After administration of iron dextran complex, evidence of a therapeutic response can be seen in a few days as an increase in the reticulocyte count.

Although serum ferritin is usually a good guide to body iron stores, the correlation of body iron stores and serum ferritin may not be valid in patients on chronic renal dialysis who are also receiving iron dextran complex.

Although there are significant variations in body build and weight distribution among males and females, the accompanying table and formula represent a convenient means for estimating the total iron required. This total iron requirement reflects the amount of iron needed to restore hemoglobin concentration to normal or near normal levels plus an additional allowance to provide adequate replenishment of iron stores in most individuals with moderately or severely reduced levels of hemoglobin. It should be remembered that iron deficiency anemia will not appear until essentially all iron stores have been depleted. Therapy, thus, should aim at not only replenishment of hemoglobin iron but iron stores as well.

---

### Hepcidin and iron status in patients with inflammatory bowel disease undergoing induction therapy with vedolizumab or infliximab [^116u7ss4]. Inflammatory Bowel Diseases (2023). Medium credibility.

Data Collection

Demographic, anthropometric, and extensive clinical data (Table 1) were extracted from medical records. These data were documented at the start of induction therapy. Biochemical parameters were collected at baseline, week 6, and week 14 of induction therapy with either IFX or VEDO. The following biochemical measurements were extracted from medical records: hemoglobin, mean corpuscular volume, white blood cell count (WBC), neutrophils, platelets, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase, albumin, creatinine, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration), serum iron, ferritin, transferrin, total iron binding capacity (TIBC), transferrin saturation (TSAT), and fecal calprotectin (fCal). Montreal classification at baseline and data on clinical, biochemical, and endoscopic or radiologic disease activity were extracted from medical records.

Table 1.
Baseline demographic and clinical characteristics of the study population

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^115oKPk3]. KDIGO (2012). Medium credibility.

Regarding medical management for chronic kidney disease, more specifically with respect to management of anemia, iron therapy, KDIGO 2012 guidelines recommend to consider administering a trial of IV iron (or alternatively a 1–3 month trial of oral iron therapy in patients with non-dialysis CKD) in adult patients with CKD on ESA therapy not receiving iron supplementation if an increase in hemoglobin concentration or a decrease in ESA dose is desired and transferrin saturation is < 30% and ferritin is < 500 ng/mL.

---

### Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3–5: an analysis of a randomized trial (RESCUE) [^114A2x8B]. Journal of the American Society of Nephrology (2024). Medium credibility.

Effects of Ziltivekimab on Biomarkers of Iron Homeostasis

Ziltivekimab was associated with a statistically significant increase in serum iron levels, TIBC, and transferrin saturation compared with placebo across all doses (Table 3). Reticulocyte Hb levels increased significantly in the ziltivekimab 15 and 30 mg treatment groups. No significant changes were observed for ferritin or hepcidin in the ziltivekimab treatment groups.

Table 3
Change From Baseline to Week 12 for Additional Biomarkers of Anemia

Data on changes in levels of anemia biomarkers, stratified by Hb levels at baseline, are presented in. Overall, these subgroup data aligned with the overall population, with significant increases in serum iron levels and TIBC compared with placebo in both the < 11 and ≥ 11 g/dl subgroups across most ziltivekimab doses. A significant increase in reticulocyte levels was observed in the baseline Hb ≥ 11 g/dl subgroup for the 15 and 30 mg treatment groups. For transferrin saturation, changes versus placebo were significant for the subgroups with baseline Hb ≥ 11 g/dl, but not for subgroups with baseline Hb < 11 g/dl, with the exception of the ziltivekimab 15 mg group.

When transferrin saturation was analyzed by baseline transferrin saturation quartiles (quartile 1: ≤ 15.5%, quartile 2: > 15.5% and ≤ 19.0%, quartile 3: > 19.0% and ≤ 23.5%, and quartile 4: > 23.5%), transferrin saturation was similar for the corresponding placebo and pooled ziltivekimab quartile groups at baseline. At week 12, transferrin saturation decreased across most quartiles with placebo (with the exception of quartile 1), but increased markedly in all quartiles for ziltivekimab, including in higher quartiles of transferrin saturation at baseline. In an analogous quartile analysis of baseline hsCRP levels by baseline transferrin saturation, there was an inversely proportional relationship between transferrin saturation quartiles and hsCRP.

Adverse Events

Ziltivekimab was well tolerated, with no major safety concerns reported (Table 4). The numbers of cases of AKI, anemia, and iron deficiency anemia were low and similar across treatment groups. One case of sustained grade 2 neutropenia was reported in the ziltivekimab 7.5 mg group; there were no cases of grade 3 or 4 neutropenia in any treatment arm. No cases of grade 2–4 sustained thrombocytopenia were reported.

Table 4
RESCUE Trial Safety Outcomes Relevant to Anemia and CKD

---

### KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD [^116A1nuJ]. American Journal of Kidney Diseases (2013). Medium credibility.

KDIGO anemia in CKD — trial of iron in ESA-treated adults is suggested under threshold criteria. For adult chronic kidney disease (CKD) patients on erythropoiesis-stimulating agent (ESA) therapy who are not receiving iron supplementation, the guideline states "we suggest a trial of IV iron (or in CKD ND patients alternatively a 1–3 month trial of oral iron therapy)" when an increase in hemoglobin (Hb) or a decrease in ESA dose is desired and "TSAT is ≤ 30% and ferritin is ≤ 500 ng/ml (≤ 500 µg/l)".

---

### Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick? [^112Vtput]. Hematology: American Society of Hematology. Education Program (2020). Medium credibility.

While iron deficiency remains the most common cause of anemia worldwide, low iron stores are associated with symptoms regardless of the presence of typical microcytic, hypochromic anemia and may be hard to recognize in patients with concurrent inflammation. Diagnosing and treating iron deficiency become more of a challenge because markers of iron status are influenced by low-grade inflammation present in common conditions, such as chronic kidney disease, cirrhosis, or heart failure. Here I present a pragmatic way of interpreting diagnostic lab tests to help clinicians recognize patients who are most likely to benefit from iron supplementation, choose between oral and parenteral administration, and make personalized decisions when patients do not fit usual guidelines.

---

### The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study [^117NbAdp]. Nephrology, Dialysis, Transplantation (2010). Low credibility.

Introduction

Annual blood losses of around 2.5 l place patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) at particularly high risk of iron store depletion with subsequent iron deficiency anaemia (IDA). Iron deficiency can be defined as absolute or functional. Absolute iron deficiency develops as the body's iron stores become depleted to such a low level that not enough iron is available for the production of haemoglobin (Hb). This is usually indicated by a decline in serum ferritin levels to ∼ < 15 µg/l in patients with normal kidney function, but is much higher in patients undergoing HD as a result of chronic inflammation, and is associated with elevated levels of C-reactive protein (CRP). This functional iron deficiency describes the state when iron cannot be mobilized from stores (despite an adequate dietary supply) to meet the demand for erythropoiesis. Serum ferritin levels can appear normal (200–500 µg/l) or increased in chronic inflammatory disorders, while levels of transferrin saturation (TSAT), which is serum iron divided by total iron-binding capacity, will be low (typically < 20%), indicating limited transport of iron to the erythron for erythropoiesis.

The primary therapeutic aim in anaemic patients undergoing HD is to restore Hb levels and iron stores to internationally recommended target ranges. To attain the Hb target range of 11.0–12.0 g/dl (not exceeding 13.0 g/dl), patients are given supplemental intravenous (i.v.) iron as an adjunct to erythropoiesis-stimulating agents (ESAs). For patients undergoing HD, i.v. iron substitution is the recommended route of administration and has become the standard treatment for optimizing a patient's iron status. Nevertheless, older i.v. iron formulations have their limitations, including the potential for immunogenic reactions induced by dextran molecules (iron dextran), dose limitations, a slow rate of administration (to prevent acute, labile iron-induced toxicity and vasoactive reactions) and the compulsory requirement for a test dose (iron dextrans in USA and Europe). All-event reporting rates were 29.2, 10.5 and 4.2 reports per million 100 mg iron dose equivalents, while all-fatal-event reporting rates were 1.4, 0.6 and 0.0 reports per million 100 mg dose equivalents for iron dextran, sodium ferric gluconate and iron sucrose, respectively.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^11529EC7]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy, monitoring, KDIGO 2012 guidelines recommend to measure hemoglobin concentration in patients with anemia of CKD when clinically indicated and at least at the following intervals according to the stage of CKD:

- stage 3–5, non-dialysis or peritoneal dialysis: every 3 months

- stage 5, on hemodialysis: every month.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^113TEwKM]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy (upper limit), UKKA 2025 guidelines recommend to do not allow serum ferritin to exceed 600 mcg/L in patients not on hemodialysis who are treated with iron. Review iron management when ferritin is ≥ 500 mcg/L, recognizing that levels > 800 mcg/L may indicate iron toxicity.

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^116BWATz]. American Journal of Kidney Diseases (2007). Medium credibility.

Scope and safety context for hemoglobin targets — Hb targets apply exclusively to patients receiving ESA, and Hb targets are not intended to apply to the treatment of iron deficiency in patients receiving iron therapy without the use of ESAs; warnings, indications, precautions, and instructions for dosing and administration of ESAs are available from national regulatory agencies, including the United States Food and Drug Administration (FDA), and product package inserts.

---

### The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients [^115Cm9CA]. Nephrology, Dialysis, Transplantation (2014). Low credibility.

Iron is essential for most living organisms but iron excess can be toxic. Cellular and systemic iron balance is therefore tightly controlled. Iron homeostasis is dysregulated in chronic kidney disease (CKD) and contributes to the anemia that is prevalent in this patient population. Iron supplementation is one cornerstone of anemia management in CKD patients, but has not been rigorously studied in large prospective randomized controlled trials. This review highlights important advances from genetic studies and animal models that have provided key insights into the molecular mechanisms governing iron homeostasis and its disturbance in CKD, and summarizes how these findings may yield advances in the care of this patient population.

---

### Canagliflozin and iron metabolism in the CREDENCE trial [^114N8DyV]. Nephrology, Dialysis, Transplantation (2025). Medium credibility.

Our results complement data in patients with heart failure with reduced ejection fraction, where dapagliflozin increased hemoglobin and hematocrit, and improved other anemia-related outcomes regardless of iron deficiency. This effect on anemia is distinct from erythropoiesis-stimulating agents, which are less effective in patients with iron deficiency, and underscore the concept that SGLT2 inhibitors improve iron availability but may not worsen iron deficiency. The relatively small effect of canagliflozin on TIBC and the non-significant effect on TSAT in the current study are compatible with this notion. Our findings extend previous observations of the effects of SGLT2 inhibitors on iron metabolism to patients with CKD, in whom anemia and iron deficiency are highly prevalent, especially as kidney function declines.

Iron is a fundamental element important in cardiac myocyte and mitochondrial function. Iron deficiency, irrespective of anemia, has been consistently shown to be strongly linked to the risk of cardiovascular events in people with CKD and heart failure. Several lines of evidence suggest that improvements in iron utilization may contribute to the beneficial cardiovascular effects of SGLT2 inhibitors, particularly for preventing heart failure. In a randomized trial, treatment with empagliflozin increased myocardial iron uptake as measured by cardiac magnetic resonance imaging in patients with heart failure without diabetes. These improvements in myocardial iron content were associated with favorable changes in left ventricular mass, volumes and function. Additionally, mediation analyses indicate that changes in hemoglobin and hematocrit are the most important statistical mediators of the benefits of SGLT2 inhibitors on cardiovascular outcomes. Further research is necessary to assess the mechanistic link between the effect of canagliflozin on iron metabolism and their cardiovascular benefit in patients with CKD.

---

### Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease [^111v4N3J]. American Journal of Nephrology (2017). Low credibility.

Background

Therapeutic options for the treatment of anemia secondary to chronic kidney disease (CKD) remain limited. Vadadustat (AKB-6548) is an oral hypoxia-inducible factor prolyl-hydroxylase domain (HIF-PHD) inhibitor that is being investigated for the treatment of anemia secondary to CKD.

Methods

A phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial (NCT01381094) was undertaken in adults with anemia secondary to CKD stage 3 or 4. Eligible subjects were evenly randomized to 5 groups: 240, 370, 500, or 630 mg of once-daily oral vadadustat or placebo for 6 weeks. All subjects received low-dose supplemental oral iron (50 mg daily). The primary endpoint was the mean absolute change in hemoglobin (Hb) from baseline to the end of treatment. Secondary endpoints included iron indices, safety, and tolerability.

Results

Ninety-three subjects were randomized. Compared with placebo, vadadustat significantly increased Hb after 6 weeks in a dose-dependent manner (analysis of variance; p < 0.0001). Vadadustat increased the total iron-binding capacity and decreased concentrations of ferritin and hepcidin. The proportion of subjects with at least 1 treatment-emergent adverse event was similar between vadadustat- and placebo-treated groups. No significant changes in blood pressure, vascular endothelial growth factor, C-reactive protein, or total cholesterol were observed. Limitations of this study included its small sample size and short treatment duration.

Conclusions

Vadadustat increased Hb levels and improved biomarkers of iron mobilization and utilization in patients with anemia secondary to stage 3 or 4 CKD. Global multicenter, randomized phase 3 trials are ongoing in non-dialysis-dependent and dialysis-dependent patients.

---

### Canagliflozin and iron metabolism in the CREDENCE trial [^116AM9G4]. Nephrology, Dialysis, Transplantation (2025). Medium credibility.

KEY LEARNING POINTS

What was known:

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular events and chronic kidney disease (CKD) progression in patients with CKD.
In patients with heart failure, the SGLT2 inhibitor dapagliflozin increased red blood cell mass and improved iron availability.
In this post hoc analysis of the CREDENCE trial, we assessed the effect of canagliflozin on circulating iron markers in patients with CKD and type 2 diabetes.

This study adds:

This study found that canagliflozin reduced ferritin and increased total iron binding capacity over 12 months compared with placebo.
Canagliflozin increased hemoglobin and corrected anemia regardless of iron deficiency, defined as transferrin saturation < 20% at baseline.
The risk reductions for cardiovascular, kidney and mortality outcomes with canagliflozin were also consistent across baseline iron deficiency.

Potential impact:

These findings suggest that canagliflozin increased iron utilization in patients with CKD and type 2 diabetes.
Our results support future studies to assess the interaction between SGLT2 inhibitors, ferrokinetics, and iron therapies in this population.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^1124wFVr]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to ESAs, monitoring, KDIGO 2012 guidelines recommend to assess iron status (ferritin and transferrin saturation) more frequently when initiating or increasing ESA dose, when there is blood loss, when monitoring response after a course of IV iron, and in other circumstances where iron stores may become depleted.

---

### Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia [^112Mz6xg]. Nephrology, Dialysis, Transplantation (2021). Medium credibility.

In NDD-CKD, the extent to which serum biomarkers of ID, as assessed by TSAT and ferritin, are associated with worse health-related quality of life (HRQoL), and particularly independent from anemic states, has not been previously investigated. We therefore designed an analysis using data from chronic kidney disease outcomes and practice patterns study (CKDopps), an ongoing international prospective cohort study of adult NDD-CKD patients, to address the following hypotheses: low TSAT, including its combinations with ferritin (i.e. high and low ferritin), is associated with worse HRQoL, particularly in physical domains, among NDD-CKD persons; and the association between serum biomarkers of iron stores and HRQoL is not mediated or modified by hemoglobin (Hb) levels.

---

### Is hepcidin the star player in iron metabolism in chronic kidney disease? [^112FjS3N]. Kidney International (2009). Low credibility.

It is well known that abnormal iron metabolism contributes to the development of anemia in chronic kidney disease (CKD) patients. Hepcidin is a circulating peptide produced in the liver that regulates efflux of iron from the cells. Ashby et al. measured the serum level of hepcidin using a new assay. Although the new assay produced mixed results and needs to be verified, these data suggest that hepcidin is not the only star player in iron metabolism in CKD.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^116rgg8o]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy, iron deficiency with anemia, KDIGO 2012 guidelines recommend to administer oral iron (or IV iron in patients with hemodialysis-dependent CKD) when transferrin saturation is < 20% and ferritin is < 100 ng/mL in pediatric patients with anemia of CKD not on iron or ESA therapy.

---

### Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives [^114JLXDd]. European Heart Journal (2013). Low credibility.

Circulating iron bound to transferrin (TIBC, total iron binding capacity — by transferrin) reflects the amount of iron available for metabolizing target cells. Importantly, neither serum iron nor serum transferrin alone should be used as biomarkers of iron status. Instead, transferrin saturation (Tsat), the per cent of transferrin that has iron bound to it (ratio of serum iron and TIBC × 100), is recommended. Reduced Tsat (< 20%) is considered a surrogate of insufficient iron available for metabolizing cells. With malnutrition accompanying chronic diseases, liver synthesis and blood transferrin levels may be low, which can artificially increase Tsat disproportionate to the iron content.

When serum ferritin is between 100 and 300 µg/L (which is frequent in patients with chronic diseases with pro-inflammatory activation), the diagnosis of ID is more complex. Such values are usually associated with normal/slightly increased intracellular iron stores and the diagnosis of absolute ID cannot be made. If there is restricted iron delivery to target cells (reduced Tsat < 20%), functional ID can be diagnosed.

---

### Canagliflozin and iron metabolism in the CREDENCE trial [^113yJWSv]. Nephrology, Dialysis, Transplantation (2025). Medium credibility.

INTRODUCTION

Disordered iron metabolism and anemia occur commonly in patients with type 2 diabetes and chronic kidney disease (CKD). Large observational studies in patients with CKD have indicated that iron deficiency is independently associated with cardiovascular events and all-cause death, regardless of anemia. Large-scale randomized trials in patients with heart failure have shown that intravenous iron administration reduces the risk of hospitalization for heart failure or cardiovascular death, independent of hemoglobin levels. In patients with dialysis-dependent kidney failure, a proactive high-dose intravenous iron treatment regimen showed a lower risk of major cardiovascular events or death as compared with a reactive low-dose regimen. These data suggest iron deficiency, whether absolute or functional, may have an important impact on cardiovascular outcomes in patients with CKD or heart failure.

In addition to their benefits on renal and cardiovascular outcomes including heart failure, post hoc analyses of large clinical trials demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors have favorable effect on anemia. Previously these changes in hematological parameters were thought to reflect hemoconcentration. However, a recent mechanistic study revealed that the increase in urine output by SGLT2 inhibitors is only acute and transient. In contrast to this, the increase in hemoglobin is gradual and peaks around 4 months. In addition, another clinical study observed a rise in reticulocyte count with dapagliflozin. These data suggest that erythropoiesis induced by SGLT2 inhibitors at least partly contributes to the increase in red blood cell mass.

In patients with heart failure with reduced ejection fraction, dapagliflozin decreased circulating transferrin saturation (TSAT), ferritin and hepcidin, and increased total iron binding capacity (TIBC), suggesting that SGLT2 inhibition might increase iron use by addressing hepcidin-induced functional iron blockade. In a mechanistic randomized trial in patients with heart failure, empagliflozin reduced ferritin and increased myocardial iron content on cardiac magnetic resonance imaging. Together with evidence demonstrating the benefits of iron administration in heart failure, these effects of SGLT2 inhibitors on markers of iron metabolism suggest that improvements in iron utilization may contribute to their clinical benefits on heart failure–related outcomes. However, there are few, if any, data regarding the impact of SGLT2 inhibitors on iron metabolism in patients with CKD. Any effects of SGLT2 inhibitors on iron metabolism in CKD would be important to understand, given the high prevalence of iron deficiency and anemia in this population, especially as kidney function declines.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^113P2yHo]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy, safety, KDIGO 2012 guidelines recommend to avoid administering IV iron in patients with active systemic infections.

---

### Chronic kidney disease: prevention, diagnosis, and treatment [^1116ZdUv]. American Family Physician (2023). High credibility.

Regarding diagnostic investigations for chronic kidney disease, more specifically with respect to screening for anemia, AAFP 2023 guidelines recommend to measure hemoglobin levels at least annually in patients with CKD stage ≥ 3 and as indicated in patients with less severe disease.

---

### Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia [^113xVXt8]. Nephrology, Dialysis, Transplantation (2021). Medium credibility.

Our study provides new insights for potential strategies to improve PROs in NDD-CKD care. Iron treatments are widely available and safe, and ID is highly prevalent among patients with CKD. It will be important to design intervention studies to analyze the hypothesis raised by our observation (and supported by trials in HF) that treating ID, even in the absence of anemia, may improve the perception of physical function, the capacity to execute physical activities and, importantly, the ability to perform daily activities.

In conclusion, low TSAT, as well as both low and high ferritin levels, is associated with worse physical HRQoL in NDD-CKD patients, even after adjustment or stratification by Hb level. RCTs addressing the potential impact of iron replacement therapies on the HRQoL of NDD-CKD individuals with and without anemia are needed to confirm the associations observed in this cohort.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^113E7KXz]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy (upper limit), UKKA 2025 guidelines recommend to consider tailoring the approach to assess the risk and benefit of initiating a proactive IV iron protocol in patients who have been on hemodialysis for > 12 months.

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^115SMpw9]. American Journal of Kidney Diseases (2007). Medium credibility.

KDOQI anemia in chronic kidney disease — iron evaluation and monitoring specify that TSAT should be > 20%, and ferritin > 100 ng/mL before starting epoetin; the guideline states "Monitor TSAT and ferritin regularly, provide iron", with iron status tests specified as monthly during initial ESA treatment and at least every 3 months during stable ESA treatment.

---

### Optimal oral iron therapy for iron deficiency anemia among US veterans [^117DGig8]. JAMA Network Open (2024). High credibility.

Importance

Optimal oral iron supplementation strategy is unclear in patients with iron deficiency anemia (IDA) who have either normal kidney function (NKF) or chronic kidney disease (CKD).

Objective

To investigate the association of different oral iron supplementation strategies with the change in hemoglobin and iron indices among patients with IDA with either NKF or CKD.

Design, Setting, and Participants

This retrospective cohort study was conducted between 2009 and 2019 at nationwide Veterans Health Administration facilities. Eligible participants included veterans with IDA (defined as hemoglobin < 12 g/dL and either iron saturation < 20% or ferritin < 50 ng/mL) who received their first outpatient prescription of oral iron. Patients were further divided into those with NKF (estimated glomerular filtration rate > 60 mL/min/1.73 m2) and CKD (estimated glomerular filtration rate ≥ 15 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Data analysis was conducted from February to October 2023.

Exposures

Patients were classified into 3 groups based on their oral iron dosing schedule: daily (once a day), multiple doses per day (MDD; ≥ 2 times per day), or alternate-day dose (ADD).

Main Outcomes and Measures

The primary outcomes were change of hemoglobin, ferritin, total iron binding capacity (TIBC), and iron saturation (ISAT), which were calculated with linear mixed-effects models.

Results

A total of 71 677 veterans with IDA (63 202 male [88.2%] and 8475 female [11.8%]; mean [SD] age, 68.47 [13.09] years), including 47 201 with NKF and 24 476 with CKD, were identifed. In patients with NKF in the daily group, hemoglobin increased from baseline (estimated per-30-day difference [SE], 0.27 [0.00] g/dL; P < .001). In comparison with the daily group, hemoglobin increased more in the MDD group (estimated per-30-day difference [SE], 0.08 [0.03] g/dL; P < .001), but no difference was noted in the ADD group (estimated per-30-day difference [SE], -0.01 [0.01] g/dL; p = 0.38). Ferritin, ISAT, and TIBC results were similar, except TIBC showed less change in the ADD group compared with the daily group. Patients with CKD showed similar trends but smaller magnitudes in changes. Among patients with NKF, the adjusted mean increase in hemoglobin was 1.03 g/dL (95% CI, 1.01–1.06 g/dL) for those in the daily group, 1.38 g/dL (95% CI, 1.36–1.40 g/dL) for those in the MDD group, and 0.93 g/dL (95% CI, 0.84–1.02 g/dL) for those in the ADD group at 90 days. Among patients with CKD, the adjusted mean increase in hemoglobin was 0.71 g/dL (95% CI, 0.68–0.73 g/dL) for those in the daily group, 0.99 g/dL (95% CI, 0.97–1.01 g/dL) for those in the MDD group, and 0.62 g/dL (95% CI, 0.52–0.73 g/dL) for those in the ADD group at 90 days.

Conclusions and Relevance

In this retrospective cohort study of veterans with IDA, there was no significant difference in the improvement of hemoglobin and iron indices between daily and ADD groups, but quickest improvement was observed in the MDD group. These findings suggest that the choice of oral iron therapy should depend on the rapidity of response desired and patient preference due to adverse effects.

---

### Renal association clinical practice guideline on anaemia of chronic kidney disease [^111cDi1f]. BMC Nephrology (2017). Low credibility.

Tests limitations

HRC estimation is a useful test for assessment of iron availability but is limited by the effect of sample storage time and need for special analysers. Long sample storage time (> 6 h) may spuriously increase HRC. Because a fresh sample is needed, this measure may not be practical in routine clinical practice.
If using percentage of hypochromic red blood cells from a fresh sample is not possible, reticulocyte Hb content (CHr) or Ret-Hb could be a suitable alternative.
If testing for CHr (or Ret-Hb) is not feasible, it is preferable to test ferritin and TSAT together because the combination provides an important insight into erythropoiesis, iron storage and iron availability to bone marrow.
Low serum ferritin is diagnostic of iron deficiency. High serum ferritin, in addition to expressing the adequacy of iron stores, could be due to inflammatory conditions. TSAT is influenced by nutritional status, timing and inflammation. TSAT is also limited by high day to day variations.

In patients with CKD not on dialysis, serum ferritin levels less than 25 ng/mL in males and less than 12 ng/mL in females suggest depletion of iron stores as a cause of anaemia; but serum ferritin level is less reliable in the evaluation of iron stores in HD patients, because ferritin level is affected by other factors in addition to iron storage status. In relatively healthy HD patients, before widespread use of IV iron therapy, the finding of a ferritin level less than 50 ng/mL was not uncommon and was associated with absent bone marrow iron in approximately 80% of patients. However, in HD patients with several co-morbidities, absent iron stores may still be found at ferritin levels approaching or even exceeding 200 ng/mL.

Iron-deficiency is most likely to contribute to anaemia when TSAT results are less than 20%. However, the clinical utility of TSAT is impaired by the absence of a diagnostic threshold above which deficient iron utilisation can be excluded as a cause of anaemia.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^111CX2fR]. BMC Nephrology (2025). High credibility.

Regarding screening and diagnosis for anemia of chronic kidney disease, more specifically with respect to diagnostic criteria, UKKA 2025 guidelines recommend to consider using a transferrin saturation < 20% and a normal or elevated ferritin level to define functional iron deficiency in patients with non-dialysis-dependent CKD or maintained on peritoneal dialysis and in those receiving hemodialysis. Recognize that normal or high serum ferritin values do not exclude iron deficiency, as it could be due to other causes such as infection or inflammation.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^117EMSCv]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to measure the percentage of hypochromic red cells as the best-established variable and reticulocyte hemoglobin content as the next most established option for the identification of functional iron deficiency.

---

### Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia [^112KhNGz]. Nephrology, Dialysis, Transplantation (2021). Medium credibility.

INTRODUCTION

In biological systems, iron exerts essential functions and can potentially result in cell toxicity, particularly in the context of increased intracellular iron content resulting in oxidative injury, which explains the complex regulation of iron metabolism in human physiology. On the other hand, a decrease in iron availability in the body results not only in iron deficiency (ID) anemia, but also in a disarrangement of the energy metabolism, particularly in muscle cells, given that iron is essential for the synthesis of major proteins in a wide range of intracellular pathways.

A precise diagnosis of ID can be achieved by the confirmation of reduced iron content in the bone marrow, although the clinical use of this evaluation is not practical. Although far from ideal, the most commonly used parameters to assess iron status in clinical practice are transferrin saturation (TSAT) and ferritin. Based on these biochemical parameters, there are two main ID subtypes: absolute ID, loosely defined as low TSAT and low ferritin levels, and functional ID, defined as high ferritin combined with low TSAT. While the former represents the most common subtype in the general population, the latter is commonly found in chronic inflammatory states, such as heart failure (HF) and chronic kidney disease (CKD). In fact, functional ID results in part from increased hepcidin levels, which reduce iron release from the reticuloendothelial system, thereby restricting iron availability for metabolic functions.

ID is a common finding in nondialysis-dependent CKD (NDD-CKD), occurring in up to 50% of patients with anemia. Current CKD guidelines recommend that screening for ID should be done mainly in the context of anemia. Previous studies have shown that even in this restricted strategy of testing for iron parameters, patients are often left underevaluated and undertreated for ID.

The clinical effects of ID on muscle metabolism and function are well described in chronic conditions having a similar pathophysiological basis for ID, such as HF. In HF patients, ID, independent from anemia, has been associated with worse functional and patient-reported outcomes (PROs) in observational studies. Randomized controlled trials (RCTs) have confirmed the benefits of ID treatment in HF, regardless of anemia status, with improvements ranging from patient-reported to clinical outcomes. In NDD-CKD patients, ID, both functional and absolute, has been associated with worse clinical outcomes in observational studies; RCTs, however, have primarily focused on the erythropoietic effects of iron replacement therapy.

---

### Sixteen years post radiotherapy of nasopharyngeal carcinoma elicited multi-dysfunction along PTX and chronic kidney disease with microcytic anemia [^111PLbUi]. BMC Urology (2014). Low credibility.

Table 3
Biochemical tests of serum

TIBC: Total iron binding capacity. e-GFR: estimated glomerular filtration rate.

s-GOT: serum glutamate-oxaloacetate transaminase. s-GPT: serum glutamate-pyruvate transaminase.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^116RmEyQ]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to measure serum ferritin levels in the assessment and management of patients with all forms of iron-restricted erythropoiesis, including functional iron deficiency. View values < 12 mcg/L indicative for absent iron stores.
Do not exclude the possibility of functional iron deficiency in case of values as high as 1,200 mcg/L in patients with CKD, and recognize that some such patients may respond to IV iron therapy. View a serum ferritin concentration of < 100 mcg/L in non-dialysis patients or < 200 mcg/L in chronic hemodialysis patients as predictive of iron deficiency and potentially good response to IV iron therapy.
Do not use values above the suggested cut-offs to guide iron therapy. Use serum ferritin values > 1,200 mcg/L to ascertain obtaining evaluation for potential iron overload.

---

### Iron dosing in kidney disease: inconsistency of evidence and clinical practice [^115Gg7am]. Nephrology, Dialysis, Transplantation (2015). Low credibility.

The management of anemia in patients with chronic kidney disease (CKD) is difficult. The availability of erythropoiesis-stimulating agents (ESAs) has increased treatment options for previously transfusion-requiring patients, but the recent evidence of ESA side effects has prompted the search for complementary or alternative approaches. Next to ESA, parenteral iron supplementation is the second main form of anemia treatment. However, as of now, no systematic approach has been proposed to balance the concurrent administration of both agents according to individual patient's needs. Furthermore, the potential risks of excessive iron dosing remain a topic of controversy. How, when and whether to monitor CKD patients for potential iron overload remain to be elucidated. This review addresses the question of risk and benefit of iron administration in CKD, highlights the evidence supporting current practice, provides an overview of standard and potential new markers of iron status and outlines a new pharmacometric approach to physiologically compatible individualized dosing of ESA and iron in CKD patients.

---

### Routine laboratory testing in hemodialysis: how frequently is it needed? [^1128Nzoa]. BMC Nephrology (2022). Medium credibility.

Background

Hemodialysis is the most common form of renal replacement therapy worldwide. Hemodialysis regimens can differ among patients but chronic hemodialysis patients have usually three sessions per week with each dialysis session lasting three to five hours. They are usually monitored by routine laboratory testing to ensure dialysis adequacy and detect complications associated with chronic kidney disease stage 5 on dialysis (CKD stage 5D) such as anemia, mineral bone disorders and electrolytes' disturbances. The best practice worldwide suggests to draw a monthly blood test for these patients. Nevertheless, this routine is not based on solid evidence.

The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline on the management of chronic kidney disease-mineral bone disorder (CKD-MBD) suggests measuring serum calcium and serum phosphate every one to three months and serum parathyroid hormone (PTH) every three to six months. In CKD stage 5D patients, laboratory parameters should fall within CKD-MBD KDIGO targets: maintaining serum PTH two to nine times the top margin of normal, avoiding hypercalcemia and lowering serum phosphate toward the normal range. In the absence of robust scientific evidence, KDIGO also recommends monitoring hemoglobin (Hb) every month and both ferritin and transferrin saturation (TSAT) every three months. KDOQI anemia guidelines recommend in patients on chronic hemodialysis a Hb of 11–12 g/dL (not to exceed 13 g/dL) and administration of intravenous iron (IV iron) as long as TSAT < 20% and ferritin < 200 ng/ml. The KDIGO anemia guidelines are also aligned with KDOQI and suggest that Hb does not exceed 11.5 g/dL but they recommend intravenous iron (IV iron) be given as far as ferritin < 500 ng/mL and TSAT < 30%.

---

### ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target [^115JhGSh]. Kidney International (2014). Low credibility.

Optimal treatment algorithms for erythropoiesis-stimulating agent (ESA) and iron therapy in anemic CKD patients are lacking. Kuragano et al. evaluated hemodialysis patients over two years and report increased mortality risk and/or adverse events in those with high serum ferritin levels and high ferritin fluctuations, and an increase in adverse events in iron users. Clinical practice should avoid disproportionately high ESA or iron doses to achieve hemoglobin targets, particularly in those with significant comorbidity or ESA resistance.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^116i2X2B]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to ESAs, monitoring, UKKA 2025 guidelines recommend to ensure patients on ESAs remain iron replete before and during therapy, using either oral iron or IV iron.

---

### Canagliflozin and iron metabolism in the CREDENCE trial [^111iyJxW]. Nephrology, Dialysis, Transplantation (2025). Medium credibility.

ABSTRACT

Background

Studies in patients with heart failure have indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors increase iron use and enhance erythropoiesis. In this post hoc analysis of the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we evaluated the effects of canagliflozin on iron metabolism in patients with chronic kidney disease (CKD) and whether the effects of canagliflozin on hemoglobin and cardiorenal outcomes were modified by iron deficiency.

Methods

We measured serum iron, total iron binding capacity (TIBC), transferrin saturation (TSAT) and ferritin at baseline and 12 months. The effects of canagliflozin, relative to placebo, on iron markers were assessed with analysis of covariance. Interactions between baseline iron deficiency, defined as TSAT < 20%, and the effects of canagliflozin on hemoglobin and cardiorenal outcomes were evaluated with mixed effect models and Cox regression models, respectively.

Results

Of 4401 participants randomized in CREDENCE, 2416 (54.9%) had iron markers measured at baseline, of whom 924 (38.2%) were iron deficient. Canagliflozin, compared with placebo, increased TIBC by 2.1% [95% confidence interval (CI) 0.4, 3.8; p = 0.014] and decreased ferritin by 11.5% (95% CI 7.1, 15.7; P < .001) with no clear effect on serum iron or TSAT. Canagliflozin increased hemoglobin over the trial duration by 7.3 g/L (95% CI 6.2, 8.5; P < .001) and 6.7 g/L (95% CI 5.2, 8.2; P < .001) in patients with and without iron deficiency, respectively (P for interaction = .38). The relative effect of canagliflozin on the primary outcome of doubling of serum creatinine, kidney failure or death due to cardiovascular disease or kidney failure (hazard ratio 0.70, 95% CI 0.56, 0.87) was consistent regardless of iron deficiency (P for interaction = .83), as were effects on other cardiovascular and mortality outcomes (all P for interactions ≥ 0.10).

Conclusion

Iron deficiency is highly prevalent in patients with type 2 diabetes and CKD. Canagliflozin increased TIBC and decreased ferritin in patients with type 2 diabetes and CKD, suggesting increased iron utilization, and improved hemoglobin levels and clinical outcomes regardless of iron deficiency.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^111R9NXw]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to ESAs, treatment targets, UKKA 2025 guidelines recommend to consider applying this hemoglobin target range exclusively to patients with CKD receiving ESAs, and recognize that it is not intended for the treatment of iron deficiency in patients receiving iron therapy without the use of ESAs.

---

### Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease [^116YtRYe]. BMC Nephrology (2018). Low credibility.

Conclusion

In this study, we show that in CKD patients the highest risk for adverse outcomes with ID is observed when for the definition of ID a TSAT cutoff level lower than 10% is used. The use of the TSAT cutoff is largely independent of the level of serum ferritin. This suggests that emphasis should be placed on a low TSAT rather than ferritin levels in early stage CKD patients. Further research is needed to validate our results in terms of the effect of iron treatment on outcomes.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^11693q3v]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to recognize that the soluble transferrin receptor assay is relatively expensive and not widely available, and treatment of anemia of CKD with ESAs increases soluble transferrin receptor level. Consider obtaining soluble transferrin receptor assay, either alone or in combination with the ferritin assay, if automated measures such as percentage of hypochromic red cells, reticulocyte hemoglobin content, or reticulocyte hemoglobin equivalent are unavailable.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^116ANoLV]. KDIGO (2012). Medium credibility.

Regarding medical management for chronic kidney disease, more specifically with respect to management of anemia, iron therapy, KDIGO 2012 guidelines recommend to guide subsequent iron administration in patients with CKD based on hemoglobin responses to recent iron therapy, as well as ongoing blood losses, iron status tests (transferrin saturation and ferritin), hemoglobin concentration, ESA responsiveness and ESA dose in ESA treated patients, trends in each parameter, and the patient's clinical status.

---

### Sixteen years post radiotherapy of nasopharyngeal carcinoma elicited multi-dysfunction along PTX and chronic kidney disease with microcytic anemia [^112Q41Ep]. BMC Urology (2014). Low credibility.

Background

The hypothalamic-pituitary (h-p) unit is a particularly radiosensitive region in the central nervous system. As a consequence, radiation-induced irreversible, progressively chronic onset hypopituitarism (RIH) commonly develops after radiation treatments and can result in variably impaired pituitary function, which is frequently associated with increased morbidity and mortality.

Case Presentation

A 38-year-old male subject, previously having received radiotherapy for treatment of nasopharygeal carcinoma (NPCA) 16 years ago, appeared at OPD complaining about his failure in penile erection, loss of pubic hair, atrophy of external genitalia: testicles reduced to 2×1.5 cm; penile size shrunk to only 4 cm long. Characteristically, he showed extremely lowered human growth hormone, (HGH, 0.115 ng/mL), testosterone (< 0.1 ng/mL), total thyroxine (tT4: 4.740 g/mL), free T4 (fT4, 0.410 ng/mL), cortisol (2.34 g/dL); lowered LH (1.37 mIU/mL) and estradiol (22 pg/mL); highly elevated TSH (7.12 IU/mL). As contrast, he had low end normal ACTH, FSH, total T3, free T3, and estriol; high end normal prolactin (11.71 ng/mL), distinctly implicating hypopituitarism-induced hypothyroidism and hypogonadism. serologically, he showed severely lowered Hb (10.6 g/dL), HCT (32.7%), MCV (77.6 fL), MCH (25.3 pg), MCHC (32.6 g/dL), and platelet count (139×103/L) with extraordinarily elevated RDW (18.2%), together with severely lowered ferritin (23.6 ng/mL) and serum iron levels; highly elevated total iron binding capacity (TIBC, 509 g/dL) and transferrin (363.4 mg/dL), suggesting microcytic anemia. Severely reduced estimated glomerular filtration rate (e-GFR) (89 mL/mim/1.73 m2) pointed to CKD2. Hypocortisolemia with hyponatremia indicated secondary adrenal insufficiency. Replacement therapy using androgen, cortisol, and Ringer's solution has shown beneficial in improving life quality.

Conclusions

To our believe, we are the first group who report such complicate PTX dysfunction with adrenal cortisol insufficiency concomitantly occurring in a single patient.

---

### Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease [^1168MsjT]. BMC Nephrology (2018). Low credibility.

Background

Iron deficiency is highly prevalent in chronic kidney disease (CKD) patients. In clinical practice, iron deficiency is defined based on a combination of two commonly used markers, ferritin and transferrin saturation (TSAT). However, no consensus has been reached which cutoffs of these parameters should be applied to define iron deficiency. Hence, we aimed to assess prospectively which cutoffs of ferritin and TSAT performed optimally for outcomes in CKD patients.

Methods

We meticulously analyzed 975 CKD community dwelling patients of the Prevention of Renal and Vascular Endstage Disease prospective study based on an estimated glomerular filtration rate < 60 ml/min/1.73m 2, albuminuria > 30 mg/24 h, or albumin-to-creatinine ratio ≥ 30 mg/g. Cox proportional hazard regression analyses using different sets and combinations of cutoffs of ferritin and TSAT were performed to assess prospective associations with all-cause mortality, cardiovascular mortality, and development of anemia.

Results

Of the included 975 CKD patients (62 ± 12 years, 64% male with an estimated glomerular filtration rate of 77 ± 23 ml/min/1.73m 2), 173 CKD patients died during a median follow-up of 8.0 (interquartile range 7.5–8.7) years of which 70 from a cardiovascular cause. Furthermore, 164 CKD patients developed anemia. The highest risk for all-cause mortality (hazard ratio, 2.83; 95% confidence interval, 1.53–5.24), cardiovascular mortality (4.15; 1.78–9.66), and developing anemia (3.07; 1.69–5.57) was uniformly observed for a TSAT < 10%, independent of serum ferritin level.

Conclusion

In this study, we have shown that of the traditionally used markers of iron status, reduced TSAT, especially TSAT < 10%, is most strongly associated with the risk of adverse outcomes in CKD patients irrespective of serum ferritin level, suggesting that clinicians should focus more on TSAT rather than ferritin in this patient setting. Specific attention to iron levels below this cutoff seems warranted in CKD patients.

Electronic supplementary material

The online version of this article (10.1186/s12882–018–1021–3) contains supplementary material, which is available to authorized users.

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^113AuSYf]. American Journal of Kidney Diseases (2007). Medium credibility.

Implementation issues: In clinical practice, individualized anemia management in chronic kidney disease (CKD) requires selection of the starting Hb level, initial erythropoiesis-stimulating agent (ESA) dose/route/frequency, Hb monitoring frequency, the aspirational threshold or target Hb, and rules for sequential ESA dose adjustments, but available randomized controlled trials used either a range or a discrete value for the target Hb and published reports include little additional information to assist decision making; information is lacking about how ESA and iron therapy were actually adjusted and about comparative data to determine optimum monitoring frequency and the number of Hb results needed to reliably measure clinical performance.

---

### KDIGO clinical practice guideline for anemia in chronic kidney disease [^111vEPEQ]. KDIGO (2012). Medium credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to ESAs, monitoring, KDIGO 2012 guidelines recommend to obtain serum ferritin and transferrin saturation to assess iron status at least every 3 months during ESA therapy, and initiate or continue iron therapy accordingly.

---

### Canagliflozin and iron metabolism in the CREDENCE trial [^112yzrqP]. Nephrology, Dialysis, Transplantation (2025). Medium credibility.

Background

Studies in patients with heart failure have indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors increase iron use and enhance erythropoiesis. In this post hoc analysis of the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we evaluated the effects of canagliflozin on iron metabolism in patients with chronic kidney disease (CKD) and whether the effects of canagliflozin on hemoglobin and cardiorenal outcomes were modified by iron deficiency.

Methods

We measured serum iron, total iron binding capacity (TIBC), transferrin saturation (TSAT) and ferritin at baseline and 12 months. The effects of canagliflozin, relative to placebo, on iron markers were assessed with analysis of covariance. Interactions between baseline iron deficiency, defined as TSAT < 20%, and the effects of canagliflozin on hemoglobin and cardiorenal outcomes were evaluated with mixed effect models and Cox regression models, respectively.

Results

Of 4401 participants randomized in CREDENCE, 2416 (54.9%) had iron markers measured at baseline, of whom 924 (38.2%) were iron deficient. Canagliflozin, compared with placebo, increased TIBC by 2.1% [95% confidence interval (CI) 0.4, 3.8; p = 0.014] and decreased ferritin by 11.5% (95% CI 7.1, 15.7; P < .001) with no clear effect on serum iron or TSAT. Canagliflozin increased hemoglobin over the trial duration by 7.3 g/L (95% CI 6.2, 8.5; P < .001) and 6.7 g/L (95% CI 5.2, 8.2; P < .001) in patients with and without iron deficiency, respectively (P for interaction = .38). The relative effect of canagliflozin on the primary outcome of doubling of serum creatinine, kidney failure or death due to cardiovascular disease or kidney failure (hazard ratio 0.70, 95% CI 0.56, 0.87) was consistent regardless of iron deficiency (P for interaction = .83), as were effects on other cardiovascular and mortality outcomes (all P for interactions ≥ 0.10).

Conclusion

Iron deficiency is highly prevalent in patients with type 2 diabetes and CKD. Canagliflozin increased TIBC and decreased ferritin in patients with type 2 diabetes and CKD, suggesting increased iron utilization, and improved hemoglobin levels and clinical outcomes regardless of iron deficiency.

---

### The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial [^114eDtp7]. BMC Nephrology (2022). Medium credibility.

Assessment outcomes and their measurement

Baseline clinical information and study visits

Following screening, willing, and eligible participants were invited to attend a baseline visit, at which baseline investigations were performed (Table 2). The baseline/randomisation visit(s) occurred no more than four weeks after the patient had successfully passed a screening visit. The assessments were split over two visits if the participant preferred. Demographic data (date of birth, sex, ethnicity, smoking status, alcohol intake, body mass index (BMI), and primary aetiology of CKD were collected and recorded. A detailed disease history including cardiovascular co-morbidity and list of concomitant medications was taken. Vital signs were recorded including blood pressure. A physical examination was not required.

Table 2
Overview of trial schedule

Baseline investigations included estimated glomerular filtration rate (eGFR) and biochemical profile (BCP), full blood count (FBC), serum ferritin (SF), transferrin saturation (TSAT) and C-reactive protein (CRP). Quantification of proteinuria was carried out by measurement of urinary protein:creatinine ratio (uPCR) or if diabetic, urinary albumin:creatinine ratio (uACR) levels in a spot urine sample using standard laboratory techniques.

Muscle biopsies for participants and controls were taken on a separate visit (baseline visit 2) as they needed to be collected following 1–2 days of physical inactivity. Patients from the other London sites participating in the muscle biopsy/MRI sub-study attended for the baseline visit 2 assessments at King's College Hospital.

Qualitative interviews at entry to the trial were preferably completed on a further separate visit but could be combined with the main baseline or muscle biopsy visit if the participant preferred and was completed prior to administration of iron therapy or placebo. Interviews were conducted either face-to-face, in a quiet room separate from where the visit commenced, or via telephone depending upon the preference of the participant.

Follow-up visits

Patients completed follow-up measures at 4 weeks (± 4 days) and 12 weeks (± 14 days) after treatment.

Six minute walk test

The primary endpoint for this study was the change in 6MWT distance between baseline and 4 weeks. The outcome was also performed at 12 weeks following the 8-week exercise training programme. Distance (in metres) was measured during a self-paced, standardised 6MWT conducted around a level, 30.5 m circuit. The walk test was completed twice following sufficient rest (20 min) to allow heart rate to return to resting. The results from the second test were used for analysis.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^114goA2f]. BMC Nephrology (2025). Medium credibility.

Guideline 2.1 - Treatment of anaemia with iron therapy – Iron repletion

We recommend that people should be iron replete to achieve and maintain target Hb range, whether receiving ESA or HIF PHI or not. (1B)

Iron repletion is usually defined as:

%HRC < 6% / CHr or RET-He > 31 pg / ferritin and TSAT (> 100 µg/L and > 20%) in people with non-dialysis dependent CKD (NDD-CKD) or on PD, and > 200 µg/L in people receiving HD. (2B)
Aim for a target ferritin level greater than 100 µg/L for children with CKD receiving dialysis as well as children with CKD not on ESA or HIF-PHI therapy. (not graded)
To ensure iron repletion, iron therapy should be considered when ferritin is < 500 mcg/L and/or the TSAT < 30%.

Rationale

The definition of "adequate" iron status is:

Serum ferritin 200–700 µg/L in people receiving HD 100–600 µg/L in people with NDD-CKD and
HRC < 6%, or CHr / RET-He > 31 pg
TSAT 20–40%

The aim of iron treatment targets is to:

Minimise the ESA or HIF PHI doses required to maintain target Hb levels in those on ESA or HIF PHI therapy
Maximise the Hb level and minimise the need to initiate ESA or HIF PHI therapy to achieve target-range Hb levels in those not on ESA or HIF PHI therapy and;
Minimise potential iron toxicity

During ESA or HIF-PHI induction therapy, iron requirements will depend on the rate of erythropoiesis, the Hb deficit and ongoing iron losses. Once the target Hb has been reached and Hb stabilised, iron requirements will be dependent on ongoing iron losses. When adequate iron status is achieved, those on ESA or HIF-PHI therapy should be given maintenance iron treatment as required.

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^113BmwVV]. American Journal of Kidney Diseases (2007). Medium credibility.

KDOQI anemia in chronic kidney disease — hematology and laboratory monitoring recommends CBC with platelets, differential WBC, absolute reticulocyte count, and iron status tests on first evaluation of anemia in CKD, and specifies frequency of Hb monitoring as at least monthly in patients treated with ESA therapy.

---

### Daprodustat (Jesduvroq) [^115LMGR6]. FDA (2023). Medium credibility.

12.1 Mechanism of Action

Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC50in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.

12.2 Pharmacodynamics

Effects on Erythropoiesis

Daprodustat increases endogenous erythropoietin in a dose-dependent manner within 6 to 8 hours after administration. With repeat doses, peak increases in reticulocyte counts occur between 7 and 15 days, with subsequent increases in red blood cell production. New hemoglobin steady-state levels are reached several weeks (approximately 4 weeks in ESA-users and approximately 16–20 weeks in ESA-non-users) after initial administration.

Effects on Iron Metabolism and Utilization

Daprodustat increased serum transferrin and total iron binding capacity (TIBC) and decreased serum ferritin, transferrin saturation, and hepcidin when administered for 52 weeks in adults on dialysis with anemia due to CKD.

Cardiac Electrophysiology

At a dose 10 times the maximum recommended dose, daprodustat does not prolong the QTc interval to any clinically relevant extent.

---

### KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD [^115qvKc5]. American Journal of Kidney Diseases (2013). Medium credibility.

Iron status evaluation in chronic kidney disease (CKD) anemia on erythropoiesis-stimulating agent (ESA) therapy recommends assessing transferrin saturation (TSAT) and ferritin at least every 3 months during ESA therapy, including when deciding to start or continue iron therapy, and testing TSAT and ferritin more frequently when initiating or increasing ESA dose, with blood loss, when monitoring response after a course of IV iron, and when iron stores may become depleted (Not Graded).

---

### Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease [^1115bofh]. BMC Nephrology (2018). Low credibility.

Currently, ferritin and TSAT are the most commonly used markers in clinical setting to evaluate iron stores and iron availability. However, there are important drawbacks on the use of ferritin and TSAT as iron status parameters. Serum ferritin is an acute-phase reactant and therefore in chronic disease populations serum ferritin levels will be elevated. TSAT also has acute-phase reactivity as transferrin is elevated in the setting of acute inflammation which will lower TSAT when circulating iron remains constant. However, other markers, such as soluble transferrin receptor, percentage hypochromic red blood cells, and reticulocyte hemoglobin content, are not readily available in clinical practice, less well studied, or not used for other reasons.

Our study has strengths and limitations. Strengths are that it comprises a large cohort of CKD patients with availability of data on iron status and that it is the first study to assess all combinations of cutoffs with respect to "hard" clinical endpoints. Limitations of the current study include its observational design, that it comprises a single center study and that measurement of iron parameters were performed at a single time point, which precludes our ability to discern the impact of changes in iron parameters over time on clinical outcomes. Furthermore, the current study is only valid for early CKD, and precludes us to discern whether similar results apply for more advanced CKD stages. Another limitation might be that we did not adjust for several potential confounders in the different associations between ID and outcomes, however, the primary aim of this study is to study the prospective associations of ID with adverse outcomes using several cutoffs for ferritin and TSAT, not to investigate the mechanisms involved.

---

### Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease [^117RBFbG]. American Journal of Hematology (2022). Medium credibility.

3.4 Effects on, serum iron, and

In all four trials, serum transferrin concentrations as measured by mean TIBC were significantly increased over baseline at all times in patients randomized to vadadustat relative to those in patients randomized to darbepoetin (Figure 2 and Table S5). Mean baseline TIBC concentrations in all groups were below the lower limits of the population reference range (250–425 μg/dL), and patients with NDD‐CKD randomized to vadadustat had increases in TIBC concentrations to within the (lower) population reference range. In patients randomized to vadadustat, mean serum iron concentrations were increased from baseline in the primary (Weeks 24–36) and secondary (Weeks 40–52) efficacy evaluation periods, except in the prevalent DD‐CKD group where it remained unchanged (Figure 2 and Table S5). Over the course of both PRO 2 TECT trials and the trial in prevalent DD‐CKD, serum iron was significantly higher in the vadadustat‐treated group compared with the darbepoetin‐treated groups (Figure 2 and Table S5). Before the primary evaluation period, serum iron was significantly higher in the vadadustat‐treated group compared with the darbepoetin‐treated group in the trial in incident DD‐CKD patients (Figure 2 and Table S5).

FIGURE 2
Serum total iron binding capacity, serum iron, transferrin saturation, serum hepcidin, and serum ferritin of patients in phase 3 trials evaluating vadadustat versus darbepoetin alfa for treatment of anemia in chronic kidney disease. (A) ESA‐untreated NDD‐CKD trial; (B) ESA‐treated NDD‐CKD trial; (C) incident DD‐CKD trial; (D) prevalent DD‐CKD trial. DD‐CKD, dialysis‐dependent chronic kidney disease; NDD‐CKD, non‐dialysis‐dependent chronic kidney disease; ESA, erythropoiesis‐stimulating agent. Data points for vadadustat‐treated patients (solid blue squares) and darbepoetin‐treated patients (open red squares) represent means; error bars represent standard error of the mean. Within‐group difference from baseline: ✱ p ≤ .001, ✱✱ p ≤ .05. Between‐group difference: # p ≤ .001, ## p ≤ .05

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^112dZs6y]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy (upper limit), UKKA 2025 guidelines recommend to administer proactive high-dose IV iron in patients receiving hemodialysis, starting with 600 mcg in divided doses in the first month, followed by 400 mcg every month (or equivalent), unless ferritin is > 700 mcg/L or transferrin saturation is > 40%.

---

### Renal association clinical practice guideline on anaemia of chronic kidney disease [^112jmLXv]. BMC Nephrology (2017). Low credibility.

Guideline 1.5 - Evaluation of anaemia – Baseline investigations

We recommend that initial clinical and laboratory evaluation of anaemia should be performed prior to initiation of treatment for anaemia in CKD patients. (1A)

We recommend that laboratory evaluation should include the following tests (1B):

- Full blood count (FBC) including — in addition to the Hb concentration:

- red blood cell indices:

- mean corpuscular haemoglobin [MCH]

- mean corpuscular volume [MCV]

- mean corpuscular haemoglobin concentration [MCHC])

- white blood cell count and differential count

- platelet count

- Absolute reticulocyte count to assess bone marrow responsiveness (if indicated).

- Test to determine iron status:

- percentage of hypochromic red blood cells (% HRC), but only if processing of blood sample is possible within 6 h or

- reticulocyte Hb count (CHr) or equivalent tests e.g. reticulocyte Hb equivalent or

- combination of transferrin saturation (TSAT) and serum ferritin if the above tests are not available or the person has thalassemia or thalassemia trait

- Serum ferritin to assess iron stores.

- Plasma/serum C-reactive protein (CRP) to assess inflammation.

Based on the initial assessment we recommend in selected cases, the following tests may be useful to diagnose the cause of anaemia (1B):
Serum B 12 and serum folate concentrations.
Tests for haemolysis (plasma/serum levels of haptoglobin, lactate dehydrogenase, bilirubin, Coombs' test).
Plasma/serum and/or urine protein electrophoresis.
Hb electrophoresis.
Free light chains and bone marrow examination.

Treatment of Anaemia with iron therapy Anaemia of CKD (guidelines 2.1–2.4)

Guideline 2.1 - treatment of Anaemia with iron therapy – Iron repletion

We recommend that patients should be iron replete to achieve and maintain target Hb whether receiving ESAs or not. (1B)

Iron repletion is usually defined as:
%HRC < 6% / CHr > 29 pg/ferritin and TSAT (> 100 microgram/L and > 20%).
For children, aim for a target ferritin level greater than 100 microgram/L for CKD patients on dialysis as well as CKD patients not on ESA therapy. (ungraded)

---

### Canagliflozin and iron metabolism in the CREDENCE trial [^113FFfCs]. Nephrology, Dialysis, Transplantation (2025). Medium credibility.

DISCUSSION

The effects of SGLT2 inhibitors on iron metabolism and erythropoiesis were not anticipated when these medicines were originally developed; however, it is increasingly recognized that SGLT2 inhibitors have many effects beyond improving glycemic control including potentially important effects on hematopoiesis. In this post hoc analysis of the CREDENCE trial, we observed that treatment with canagliflozin over 1-year increased TIBC and reduced ferritin levels, suggesting that canagliflozin may have increased iron utilization. Increases in hemoglobin and hematocrit with canagliflozin were similar regardless of the presence or absence of iron deficiency at baseline, as were the effects of canagliflozin on kidney, cardiovascular and mortality outcomes. These findings identify a clear role of SGLT2 inhibitors in iron metabolism, and further confirm the consistent clinical benefits of SGLT2 inhibitors across diverse patient subsets with type 2 diabetes and CKD.

Accumulating data indicate that SGLT2 inhibitors increase red blood cell mass, possibly by increasing iron utilization as well as increasing erythropoietin synthesis. Changes in TIBC and ferritin, which occurred in parallel with reductions in hepcidin and other markers of inflammation, suggest that SGLT2 inhibitors may promote iron mobilization through reducing systemic inflammation. This phenomenon has been observed previously in patients with heart failure with reduced ejection fraction and those with type 2 diabetes without CKD. In patients with type 2 diabetes and CKD, a post hoc analysis of the DELIGHT trial reported that changes in TSAT and transferrin over 24 weeks of treatment with dapagliflozin correlated with changes in urinary and plasma interleukin-6, an inflammatory cytokine that regulates hepcidin expression. These favorable effects on iron storage and mobilization may contribute to reductions in anemia-related outcomes reported with SGLT2 inhibitors in patients with CKD.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^116V9Nh1]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy, monitoring, UKKA 2025 guidelines recommend to monitor iron status every 1–3 months in patients receiving IV iron to avoid toxicity (serum ferritin of > 800 mcg/L or transferrin saturation > 40%). View serum ferritin consistently > 800 mcg/L with no evidence of inflammation (normal CRP) as suggestive of iron overload. (1B).

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^112gMnEy]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to ESAs, initiation, UKKA 2025 guidelines recommend to do not initiate ESA therapy in the presence of absolute iron deficiency (ferritin < 100 mcg/L in non-dialysis dependent CKD and < 200 mcg/L in dialysis-dependent CKD) or functional iron deficiency (transferrin saturation < 20% with normal or elevated ferritin levels) until corrected and anemia persists. Administer iron supplements prior to or when initiating ESAs.

---

### UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease [^116ezqs9]. BMC Nephrology (2025). High credibility.

Regarding medical management for anemia of chronic kidney disease, more specifically with respect to iron therapy (iron deficiency without anemia), UKKA 2025 guidelines recommend to consider administering a trial of oral or IV iron in patients with CKD and iron deficiency without anemia and no concomitant HF to improve clinical symptoms such as restless legs.

---

### AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia [^112knLuE]. Gastroenterology (2020). High credibility.

AGA Clinical Practice Guidelines — ferritin cutoff for diagnosing iron deficiency in anemia states: In patients with anemia, the AGA recommends using a cutoff of 45 ng/mL over 15 ng/mL when using ferritin to diagnose iron deficiency. This is a Strong recommendation, high-quality evidence. In patients with inflammatory conditions or chronic kidney disease, other laboratory tests such as C-reactive protein, transferrin saturation, or soluble transferrin receptor may be needed in conjunction with ferritin to diagnose iron deficiency anemia.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^112KFCtq]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to do not measure the percentage saturation of transferrin in isolation to predict responsiveness to IV iron therapy in patients with CKD. Consider assessing the percentage saturation of transferrin to monitor response to ESAs and/or iron therapy in patients with CKD. Consider measuring the percentage saturation of transferrin in combination with either the serum ferritin concentration or measurements such as the percentage of hypochromic red cells and reticulocyte hemoglobin content for the diagnosis of functional iron deficiency.

---

### Guideline for the laboratory diagnosis of functional iron deficiency [^113nKinV]. British Journal of Haematology (2013). Medium credibility.

Regarding diagnostic investigations for anemia of chronic kidney disease, more specifically with respect to evaluation for functional iron deficiency, BCSH 2013 guidelines recommend to consider measuring red cell zinc protoporphyrin concentration as an alternative to indices of RBC hypochromia or reticulocyte hemoglobin content for assessing functional iron deficiency, recognizing that the former is less sensitive than the latter to acute changes in iron availability. Obtain measurements on washed cells, with the use of appropriate reference limits, when used in the assessment of functional iron deficiency in patients with CKD.

---

### The weak correlation between serum vitamin levels and chronic kidney disease in hospitalized patients: a cross-sectional study [^112knGx7]. BMC Nephrology (2021). Medium credibility.

Results

In total, 759 CKD patients were included in this study. Based on their eGFR values, the participants were assigned to 5 different stages according to the classification criteria described in the Methods section. The demographic and clinical characteristics of the cohort by different CKD stages were presented in Table 1. About three quarters of the patients were from stage 1 to stage 3, while the rest were from stage 4 and stage 5 equally. Patients in advanced stages were older than those in the lower stages (p < 0.001). More female patients were found in stage 1, whilst more males were found in other stages (p < 0.001). No statistically significant difference was found in the body mass index (BMI) of different stages. Serum concentrations of prealbumin, cystatin-C, alkaline phosphatase (ALP), creatinine, Hcy, urine protein, blood urea nitrogen (BUN), and uric acid increased along with the severity of CKD. The Hcy of patients with CKD at stage 1 were within the normal range, though it started increasing from stage 2 until stage 5, when Hcy levels were 2.58 times that of stage 1. Other indicators, such as hemoglobin (Hb), urine osmolality, and total iron binding capacity (TIBC) followed a decreasing trend in relation to the increasing severity of CKD.

Table 1
Demographic and Clinical characteristics of CKD patients

Note: results were from blood samples unless otherwise specified; data were expressed as median (IQR); BMI body mass index; WBC white blood cell; Hb hemoglobin; CRP C-reactive protein; BUN blood urea nitrogen; ALP alkaline phosphatase; TC total cholesterol; TG triglyceride; HDLC high-density lipoprotein cholesterol; LDLC low-density lipoprotein cholesterol; Hcy homocysteine; TIBC total iron binding capacity; HbA1c glycated hemoglobin; C3 complement component 3; C4 complement component 4

Based on the results of renal biopsy, the pathological classification of CKD patients was displayed in Table 2. The pathological subgroups of CKD were not distributed equally in different stages (p < 0.001). The major pathological type of CKD in this cohort was IgA nephropathy (40.6%) followed by membranous nephropathy at a prevalence of 31.5%.

---

### Renal association clinical practice guideline on anaemia of chronic kidney disease [^111V71Fg]. BMC Nephrology (2017). Low credibility.

There is little information in literature to guide the approach to CKD patients who show laboratory evidence of iron deficiency. Nevertheless, given the high prevalence of GI blood loss due to variety of causes in this patient population, deciding on a subsequent management plan, including endoscopy, depends on the clinical presentation. This supports the recommendation that CKD patients who present with anaemia and iron deficiency should undergo careful clinical assessment prior to the initiation of anaemia therapy.

Reduced iron availability for erythropoiesis can manifest as low mean corpuscular volume (MCV) and mean corpuscular Hb (MCH), but given the relatively long lifespan of circulating erythrocyte, this test will not reflect the existing availability of iron at the time of testing. Testing the reticulocytes for their Hb content (CHr or Ret-He) may allow more accurate estimation of iron availability, because reticulocytes are present in the circulation for 4–5 days, so give a discrete population to study. Reduced red cell Hb can be reflective of reduced haem availability or globin. Therefore, the red cell analyte values (%HRC, CHr, Ret-He) may be affected by the presence of haemoglobinopathies.

Anaemia of CKD (guidelines 2.1–2.4)

Guideline 2.1 - treatment of Anaemia with iron therapy – Iron repletion

We recommend that patients should be iron replete to achieve and maintain target Hb whether receiving ESAs or not. (1B)

Iron repletion in is usually defined as:
%HRC < 6% / CHr > 29 pg / ferritin and TSAT (> 100 microgram/L and > 20%).
For Children, aim for a target ferritin level greater than 100 microgram/L for CKD patients on dialysis as well as CKD patients not on ESA Therapy. (ungraded)

---

### A randomized trial of iron isomaltoside 1, 000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia [^116PQb5q]. Nephrology, Dialysis, Transplantation (2016). Low credibility.

The MMRM was used to compare the average change in Hb concentration from baseline to Weeks 2 and 8 with inclusion of treatment, visit, treatment × visit interactions, country and stratum [past treatment with parenteral iron (yes/no) and current eGFR between 15 and 45 mL/min/1.73 m 2 or 46 and 59 mL/min/1.73 m 2] as factors and baseline Hb as covariate. The treatment difference at the relevant weeks was derived from the interaction between treatment and visit. The same method was followed to compare the between-treatment group change in serum-iron, serum-ferritin, TSAT and TIBC from baseline to Week 1, 2, 4 or 8 and in QoL score from baseline to Week 4 or 8.

The baseline characteristics and safety data were displayed descriptively. All tests were two tailed and the significance level was 0.05.

---

### The problem with transferrin saturation as an indicator of iron' sufficiency' in chronic kidney disease [^113MtQ4x]. Nephrology, Dialysis, Transplantation (2021). Medium credibility.

After a brief review of physiological iron metabolism, we describe diagnostic tests for iron status and iron deficiency anemia in patients without chronic kidney disease (CKD) or inflammation. Thereafter we review the dysregulation of iron metabolism in CKD. Specific emphasis is placed on the role of the 'inflammatory' state that develops with the progression of CKD. It invokes changes in iron metabolism that are the exact opposite of those occurring during pure iron deficiency. As a result, transferrin saturation (TSAT) becomes a poorer index of iron availability to the bone marrow and serum ferritin no longer represents iron that can be used during erythropoiesis. We argue that serum iron may provide more information to guide iron therapy than TSAT. In other words, the emphasis on TSAT is misplaced. With the development of a number of hypoxia-inducible factor prolyl hydroxylase inhibitors, which restore iron metabolism toward the 'physiologic state', the iron indices indicating sufficient iron availability to avoid functional iron deficiency during therapy of CKD-associated anemia are likely to change. We summarize these changes in the section 'A peek into things to come!', citing the available data.

---

### Prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus in a referral diabetic clinic in the north of iran [^117G31Cb]. BMC Endocrine Disorders (2023). Medium credibility.

In conclusion, we demonstrated a high prevalence of anemia among patients with T2DM in one of the referral diabetic clinic in the north of Iran, which was associated with obesity, hypertriglyceridemia, duration of T2DM, and renal dysfunction. It is necessary to screen and evaluate anemic conditions in diabetic populations. They must be warned against the potential risk and complications of anemia and the importance of regular screening, especially among those with stated associated factors.

Table 1
Baseline characteristics of 415 participants with T2DM

Data were presented as mean (SD); FPG, LDL-C, HDL-C, Triglyceride, Ferritin and Iron were presented as median (interquartile range [IQR]); For comparison between the two groups, t-test for data with normal distribution and Mann-Whitney test ones with abnormal distribution; BMI: body mass index; FPG: fasting plasma glucose; Hb A1c: Hemoglobin A1c; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; e-GFR: estimated glomerular filtration rate e-GFR: estimated glomerular filtration rate; TIBC: total iron binding capacity; T2DM: Type 2 diabetes mellitus

Table 2
Prevalence of anemia among patients with T2DM in different subgroup

Each group of categorical variables compared by Chi-square test; GLD: glucose lowering drug; CKD: chronic kidney disease; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; T2DM: Type 2 diabetes mellitus

Table 3
Crude and adjusted odds ratios of associated factors with prevalent anemia among patients with T2DM

Multivariable logistic regression analysis was performed in 2 levels: (1) without adjustment (crude odds ratios (ORs) and 95% CI); (2) full adjustment, which is adjusted for obesity, Hb A1c, diabetes duration, GLDs usage, CKD, albuminuria, triglyceride and TC. GLD: glucose lowering drug; CKD: Chronic kidney disease; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; T2DM: Type 2 diabetes mellitus

---

### Iron deficiency in adults: a review [^111vsMJh]. JAMA (2025). Excellent credibility.

Importance

Absolute iron deficiency, defined as low iron stores with or without anemia, affects approximately 2 billion people worldwide and 14% of adults in the US. Iron-deficiency anemia, defined as low hemoglobin due to low iron stores, affects approximately 1.2 billion people worldwide, including 10 million in the US.

Observations

Absolute iron deficiency progresses from low iron stores to iron-deficiency anemia. Individuals with nonanemic iron deficiency or iron-deficiency anemia may be asymptomatic or experience fatigue, irritability, depression, difficulty concentrating, restless legs syndrome (32%-40%), pica (40%-50%), dyspnea, lightheadedness, exercise intolerance, and worsening heart failure (HF). Symptom prevalences vary depending on age, comorbidities (eg, chronic kidney disease [CKD], HF), and severity and rate of development of iron deficiency. The most common causes of iron deficiency are bleeding (menstrual, gastrointestinal), impaired iron absorption (atrophic gastritis, celiac disease, bariatric surgical procedures), inadequate dietary iron intake, and pregnancy. In high-income countries, approximately 38% of nonpregnant, reproductive-age women have iron deficiency without anemia and about 13% have iron-deficiency anemia. During the third trimester of pregnancy, iron deficiency affects up to 84% of pregnant women, based on data from high-income countries. Additional risk factors include use of nonsteroidal anti-inflammatory drugs, inflammatory bowel disease (IBD [13%-90%]), and other chronic inflammatory conditions, such as CKD (24%-85%), HF (37%-61%), and cancer (18%-82%). Testing for iron deficiency is indicated for patients with anemia and/or symptoms of iron deficiency (fatigue, pica, or restless legs syndrome) and should be considered for those with risk factors such as heavy menstrual bleeding, pregnancy, or IBD. Iron deficiency is diagnosed by low serum ferritin (typically < 30 ng/mL) in individuals without inflammatory conditions or by transferrin saturation (iron/total iron binding capacity×100) less than 20%. Causes of iron deficiency should be identified and treated. Oral iron (ferrous sulfate 325 mg/d or on alternate days) is typically first-line therapy. Intravenous iron is indicated for patients with oral iron intolerance, poor absorption (celiac disease, post-bariatric surgical procedure), chronic inflammatory conditions (CKD, HF, IBD, cancer), ongoing blood loss, and during the second and third trimesters of pregnancy.

Conclusions and Relevance

Iron deficiency and iron-deficiency anemia are common conditions that may cause symptoms such as fatigue, exercise intolerance, and difficulty concentrating. Ferritin and/or transferrin saturation are required for diagnosis and screening. Oral iron is first-line therapy for most patients. Intravenous iron is used for individuals who do not tolerate or have impaired absorption of oral iron, those with ongoing blood loss, certain chronic inflammatory conditions (IBD, CKD, HF, cancer), and during the second and third trimesters of pregnancy.

---

### Anemia, diabetes, and chronic kidney disease [^113QydfX]. Diabetes Care (2009). Low credibility.

CLINICAL PRACTICE GUIDELINES FOR EVALUATION OF ANEMIA

The NKF clinical practice guidelines for diagnosis and management of anemia in patients with CKD recommend a routine history and physical examination, a complete blood count, a reticulocyte count, evaluation of serum iron and total iron binding capacity and serum ferritin level, and a fecal test for occult blood for evaluation of anemia. Additional tests to evaluate anemia should be guided by this initial evaluation (e.g. serum folic acid, vitamin B12 level, Coombs test, etc.). Despite the high prevalence of anemia in the CKD population, treatment with erythropoietin or iron often is not used in the predialysis period. For example, nearly 70% of patients initiated on dialysis are anemic by the NKF definition but are not treated with erythropoietin, and > 50% of these patients have severe anemia (hematocrit < 30%).

---

### Renal association clinical practice guideline on anaemia of chronic kidney disease [^115jn7J4]. BMC Nephrology (2017). Low credibility.

Guideline 2.4 - treatment of Anaemia with iron therapy - upper limit for iron therapy

We recommend that serum ferritin should not exceed 800 microgram/L in patients treated with iron, and to achieve this iron management should be reviewed when the ferritin is > 500 microgram/L. (1B)

Rationale

- Iron overload is defined as increased total body iron content with the possible risk of organ dysfunction.

- There is no clinically available method that accurately determines total body iron content.

- An elevated serum ferritin does not always correlate with elevations in liver iron content.

- Magnetic resonance imaging provides a reliable assessment of tissue iron content in HD patients regularly treated with parenteral iron. However, the clinical relevance of increased liver iron remains unclear.

- Elevated serum ferritin together with elevated serum transferrin saturation remain the most clinically accurate parameter of iron overload in CKD patients.

- Discontinuation of adequate maintenance IV iron when an individual's ferritin is > 500 microgram/L produces a population mean that straddles the 500microgram/L ceiling. Ongoing iron therapy in patients with ferritin > 500 microgram/L results in a higher median ferritin outcome.

- Interpretation of iron status results and deciding on the need for further iron therapy should include a concomitant assessment of changes in Hb level and ESA dose over time. Examples:

- A dropping ferritin as well as decreasing Hb levels signifies blood loss e.g. on HD or bowel related anaemia: iron therapy is indicated; further investigation may be required depending on the clinical scenario.

- A decreasing ferritin level after initiation of ESA therapy, with a concomitant rise in Hb level indicates a response to ESA with a shift of iron from stores to bone marrow: further iron therapy is guided by target ferritin level.

- An increasing ferritin level after reduction of ESA dose to bring Hb level down to target range indicates ferritin level is rising as Hb synthesis is dropping: further iron therapy may be postponed.

---

### KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target [^115Mqgvq]. American Journal of Kidney Diseases (2007). Medium credibility.

KDOQI anemia guidelines — iron status thresholds — specify TSAT > 20% or CHr > 29 pg/cell and ferritin > 200 ng/mL in hemodialysis chronic kidney disease (HD-CKD), and TSAT > 20% and ferritin > 100 ng/mL in non-dialysis and peritoneal dialysis CKD (ND-CKD, PD-CKD); they also state insufficient evidence to recommend intravenous iron if ferritin > 500 ng/mL. The prescribing information lists TSAT > 20%, Ferritin > 100 ng/mL prior to Epogen.

---

### Assessing iron status: beyond serum ferritin and transferrin saturation [^116DvtSE]. Clinical Journal of the American Society of Nephrology (2006). Low credibility.

The increasing prevalence of multiple comorbidities among anemic patients with chronic kidney disease has made the use of serum ferritin and transferrin saturation more challenging in diagnosing iron deficiency. Because serum ferritin is an acute-phase reactant and because the inflammatory state may inhibit the mobilization of iron from reticuloendothelial stores, the scenario of patients with serum ferritin > 800 ng/ml, suggesting iron overload, and transferrin saturation < 20%, suggesting iron deficiency, has become more common. This article revisits the basis for the Kidney Disease Outcomes Quality Initiative recommendations regarding the use of serum ferritin and transferrin saturation in guiding iron therapy, then explores some of the newer alternative markers for iron status that may be useful when serum ferritin and transferrin saturation are insufficient. These newer tests include reticulocyte hemoglobin content, percentage of hypochromic red cells, and soluble transferrin receptor, all of which have shown some promise in limited studies. Finally, the role of hepcidin, a hepatic polypeptide, in the pathophysiology of iron mobilization is reviewed briefly.